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CHAPTER ONE
INTRODUCTION
Each year over 50,000 hospitalizations and 5,000 deaths within the United States
are associated with burn injury [1]. Multiple studies demonstrate that greater than 50% of
adult burn patients have a measurable blood alcohol/ethanol (EtOH) level at the time of
hospital admission [2-11]. These patients are shown to have an increased risk of infection
and higher mortality when compared to burn patients without EtOH exposure at the time
of injury [2-6, 11-13]. Yet, the exact role of EtOH on post burn pathogenesis remains to
be elucidated.
Published data from our laboratory have demonstrated that acute EtOH
intoxication prior to burn injury exacerbates intestinal T cell immune suppression and
enhances bacterial translocation [14-21], though the mechanism responsible for these
observations remain unknown. Peyer’s patches (PPs) are important intestinal secondary
lymphoid organs that play a critical role in T cell immunity, as well as gut bacterial
translocation and its containment. Current evidence suggests that T helper (Th) 17
lymphocytes are crucial in regulating mucosal immunity. Within the gut, Th17
lymphocytes help maintain intestinal immune homeostasis and protect against
extracellular bacteria [22-26]. Moreover, recent reports demonstrate that Th17
lymphocytes, in concert with dendritic cells (DCs), promote epithelial cells to release
antimicrobial peptides (AMPs) into the intestinal lumen [27-30].
1
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Interleukin (IL)-23, a cytokine released by mucosal antigen presenting cells, plays
a central role in Th17 differentiation and intestinal AMP release. IL-23 acts via signal
transducer and activator of transcription (STAT)-3 to maintain upregulation of
transcription factor retinoic acid-related orphan receptor (ROR)-γt, which is indispensible
in the expression of Th17 effector cytokines IL-17 and IL-22 and the release of AMPs
from epithelial cells [31-34].
Gaining an understanding of the mechanisms that contribute to gut immune
suppression in a murine model of EtOH intoxication and burn injury may reveal valuable
therapeutic targets for patients who sustain burn injury after EtOH exposure. The studies
performed herein utilize a murine model of EtOH exposure and scald burn injury to
examine the effects of acute EtOH intoxication on post burn Th17 effector function
within PP, explore the role of IL-23 in mediating Th17 effector function and establish a
role for IL-22 in modulating AMP expression, gut permeability and bacterial growth
following combined insult.
Hypothesis
EtOH intoxication prior to burn injury perturbs Th17 effector functions within
PPs and intestinal tissue, contributing to decreased gut immune function and increased
gut -damage.
Specific Aim 1
Demonstrate the effects of acute EtOH exposure on Th17 effector cytokines IL-17
and IL-22 in PPs and intestinal tissue after burn injury.
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Rationale
IL-17 and IL-22 are cytokines central to the effector functions of Th17 cells [23, 28, 3537]. IL-17 is crucial in the protection against gut pathogens [22-25, 38], while IL-22 is
critical in preserving epithelial barrier function as well as enhancing mucosal immunity
through induction of AMP release from epithelial cells [23, 29, 39]. Moreover,
perturbation of IL-23 following EtOH exposure and burn injury may negatively impact
Th17 effector function, facilitating gut leakiness and subsequent bacterial translocation.
Therefore, the experiments in this aim will determine if EtOH exposure prior to burn
injury results in altered IL-23 and whether this impacts Th17 effector function within the
gut. Changes in IL-23 and subsequent alterations in IL-17 and IL-22 may give insight to
possible mechanisms by which EtOH intoxication prior to burn injury leads to increased
bacterial translocation across the epithelial barrier.
Specific Aim 2
i)

Determine if modulation of IL-23, by administration of recombinant IL-23, in vitro,

ameliorates alterations in PP Th17 effector functions following EtOH intoxication and
burn injury.
ii)

Define the role ROR-γt and the aryl hydrocarbon receptor (AhR) on IL-23-

dependent modulation of IL-17 and IL-22 following EtOH intoxication and burn injury.
Rationale
IL-23, a member of the IL-12 family, is heterodimeric cytokine composed of the
p19 and p40 subunits, the p40 subunit is shared by IL-12 while the p19 subunit is unique
to IL-23 [34]. Previous studies indicate that IL-23 is required for the expression of Th17
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cytokines IL-17 and IL-22 [31, 40-42]. Many of these same studies illustrate that in vitro
and in vivo reconstitution of IL-23 with recombinant IL-23 (rIL-23) effectively restores
the IL-23/Th17 axis [31, 40, 41]. Thus, experiments in this aim are designed to test
whether reconstitution of IL-23 in vitro ameliorates Th17 effector functions following
EtOH intoxication and burn injury. Successful restoration of Th17 responses by
modulation of IL-23 may give insight into a possible mechanism by which to prevent
Th17 suppression and increased bacterial translocation following EtOH and burn injury.
Binding of heterodimeric IL-23 to its receptor complex, activates Jak2-mediated
phosphorylation of tyrosine residues on the cytoplasmic domain of the IL-23R subunit
and subsequent phosphorylation of STAT3 proteins, which homodimerize and translocate
to the nucleus to upregulate expression of ROR-γt [43]. More recent implicate the aryl
hydrocarbon receptor (AhR) in regulation of IL-22, but not IL-17 [44, 45]. Most
interesting, it remains unclear whether IL-22 is dependent on ROR-γt. These studies
highlight the crucial role of AhR in expression of IL-22, but disagree as to whether RORγt is necessary for the expression of IL-22. Moreover, neither study offers a mechanism
by which AhR modulates IL-22. Therefore, the experiments proposed in this aim will
determine the mechanism by which rIL-23 mitigates the IL-23/Th17 axis following EtOH
intoxication and burn injury.
Specific Aim 3
Elucidate the role of IL-22 in intestinal gut barrier damage and epithelial cell
antimicrobial peptide (AMP) expression following EtOH exposure and burn injury.
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Rationale
Our lab has previously demonstrated increased gut damage following combined
EtOH exposure and burn injury [20, 21, 46]. Recent findings from murine models of
EtOH induced liver damages demonstrate protective effects of IL-22 [47]. Together these
data support the use of rIL-22 in vivo to test its role in gut damage and AMP expression
following EtOH and burn injury. In these experiments, we will test the effects of IL-22
on gut leakiness following combined insult by measuring gut permeability in vivo [21]. In
regards to AMPs, Reg3γ and Reg3γ have been demonstrated to be crucial to gut
immunity [48]. Our experiments will test the effects of combined insult on AMP
expression as well as determine whether administration of IL-22 in vivo ameliorates AMP
expression.

CHAPTER TWO
REVIEW OF LITERATURE
Alcohol Intoxication and Burn Injury
An estimated more than one million burn injuries are reported yearly within the
United States [1]. These injuries translate into an approximate 500,000 emergency room
visits and 40,000 hospitalizations annually [1]. Interestingly, greater than 50% of these
injuries occur under the influence of alcohol/ethanol (EtOH) intoxication [2-11].
Furthermore, burn victims who sustain injury post EtOH exposure exhibit significantly
higher rates of morbidity and mortality than patients without EtOH exposure at the time
of injury [2-6, 11-13]. Despite clear correlations between post burn pathogenesis and
EtOH intoxication, the mechanism by which EtOH enhances post burn morbidity and
mortality remains to be elucidated. Previous data suggest that gut pathogens and their
products may play a pivotal role in the subsequent development of sepsis and multiple
organ failure reported in burn and trauma patients [6, 14, 49-58]. In line with this
hypothesis, our laboratory has demonstrated increased intestinal tissue damage, leakiness
and bacterial translocation as well as intestinal T lymphocyte suppression following
EtOH intoxication and burn injury [14-21].
Alcohol Intoxication, Burn Injury and Gut Barrier Dysfunction
Under healthy conditions the intestine maintains a barrier which prevents
intestinal bacteria and their products from reaching systemic organs. However, thisbarrier
is compromised following insult, including EtOH exposure, burn and other traumatic
injuries [12, 14, 59-61]. In such instances, intestine-derived bacteria and their products
6
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present a major clinical problem to burn/trauma victims, patients with EtOH exposure as
well as ICU patients and patients developing multiple organ failure. Several lines of
evidence indicate that burn patients who sustain injury under the influence of EtOH have
significantly longer hospital stays, require more surgical procedures and have more
complications compared to patients who sustain similar extent of burn injury but were not
intoxicated at the time of injury [2-4, 12, 13]. Moreover, intoxicated patients are more
likely to die of smaller burns [2]. Although, both chronic and acute alcohol intoxication
are likely to increase susceptibility of injured host, studies have shown that the majority
of alcohol-exposed burn-injured patients have consumed alcohol on an acute basis before
injury [4, 13]. Utilizing rodent models of acute EtOH intoxication and burn injury, we
examined the influence of acute ethanol exposure on post burn intestinal tissue damage
and leakiness. We found that as compared to either ethanol intoxication or burn injury
alone, combined insult causes intestinal tissue damage, leakiness and bacterial
translocation [14, 16, 18, 20, 21, 46]. Thus, delineating the mechanism by which EtOH
intoxication alters gut barrier integrity and function following burn injury warrants
further investigation.
Introduction to Th17 Lymphocytes
T helper (Th) cells have long been recognized as vital components of the adaptive
immune system [62, 63]. Classically, T helper cells are generated following antigen
presentation by antigen presenting cells (APCs), including dendritic cells (DCs) and
macrophages (Mϕ), in secondary lymphoid tissues [64]. Until recently, CD3+CD4+ T
helper cells were divided into either cell mediated Th1 (Interferon-γ producing) or
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humoral Th2 (Interleukin-4 producing) responses. The effector cytokines produced by
Th1 and Th2 were further predicted to regulate the development and function of the
alternate subset [62]. However, the Th1-Th2 hypothesis failed to accommodate the more
recently described IL-17 producing CD3+CD4+ Th17 cells [65]. Today, the major T
helper cell subsets include Th1, Th2, Th17 and T regulatory (Treg) cells, each of which
produce specific effector cytokines under unique transcriptional regulation [66].
Specifically, Th17 cells produce effector cytokines IL-17, IL-21 and IL-22 under the
regulation of retinoic acid-related orphan receptor ROR-γt [36, 67, 68].
IL-17 cDNA was originally cloned from murine hybridomas, where it was noted
to share 58% homology with open reading frame 13 from the T lymphotropic
Herpesvirus saimiri [69, 70]. However, IL-17 was not identified as a T helper cytokine
until 2000, when Infante-Duarte et al. demonstrated IL-17 production from T helper cells
in response to microbial lipopeptide challenge [65]. IL-22 was first cloned from T cells
and found to share 22% amino acid identity with IL-10 [71]. Further analysis confirmed
that IL-22 expression required and induced activation of the signal transducer and
activator of transcription (STAT) proteins [71]. Co-expression of IL-17 and IL-22
eventually led to the recognition of these molecules as effector cytokines of Th17 cells
[28, 72].
Th17 effector cytokines IL-17 and IL-22 have been immensely studied since the
early 2000s [30, 36, 73]. Dysregulation of Th17 effector cytokines IL-17 and IL-22 has
been implicated in psoriasis [39, 74], rheumatoid arthritis [32, 75], and both forms of
inflammatory bowel disease (IBD) [76-78]. Although, Th17 lymphocytes were first
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described as orchestrators of neutrophil recruitment and activation and as key players in
chronic inflammation and autoimmunity [36, 79], more recent evidence suggest that
Th17 lymphocytes and their effector cytokines, IL-17 and IL-22, play a crucial role in
maintaining mucosal immunity. While IL-17 has long been recognized as a
proinflammatory cytokine essential for the recruitment of neutrophils and protection
against extracellular pathogens [36], IL-22 does not appear to affect immune cells but
rather regulates the functions of epithelial cells [48].
Th17 lymphocytes have been shown to protect against various pathogens,
including Bacteriodes fragilis (B. fragilis), Klebsiella pneumoniae (K. pneumoniae) and
Candida albicans (C. albicans) [22-26]. Specifically, IL-17 was first recognized as
protective against extracellular infections when IL-17R knockouts demonstrated a
decreased ability to recruit neutrophils in response to a K. pneumoniae infection [26].
Further studies confirmed IL-17’s role in neutrophil accumulation and protection against
extracellular bacteria, when it was found to be necessary for in vivo formation of intraabdominal abscesses in response to B. fragilis [22]. Thus, Th17 lymphocytes are crucial
to the containment of various gut pathogens, including B. fragilis and K. pneumoniae,
which if not contained properly may become sources of local or systemic infection
following traumatic injury, such as alcohol intoxication and burn injury [22-25].
Moreover, Th17 lymphocytes have been proposed to enhance tight junction formation
through extracellular signal-related (ERK) mitogen-activated protein kinase (MAPK)
signaling and subsequent upregulation of tight junction proteins [80].
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Contrary to IL-17, IL-22 does not act on immune cells, but rather on epithelial
cells of the skin, pancreas, intestine, liver, lung and kidney [27, 48], where it is involved
in chemotaxis [81], antimicrobial expression [27-30], tissue repair [73, 82] and epithelial
cell survival [83, 84], proliferation [23] and differentiation [39]. Together these findings
suggest that Th17 effector cytokines must be tightly regulated in order to effectively
maintain mucosal immunity and barrier function.
IL-23, Th17 Lymphocytes and Intestinal Immunity
Under healthy conditions the gut epithelium and its associated lymphoid tissue
(GALT) provide both a physical and immunological barrier to effectively regulate the
translocation of intestinal-derived bacteria and their products. In the gut, APCs, including
DCs, continuously sample luminal content to effectively maintain innate and adaptive
components of the intestinal immune system and regulate intestinal epithelial barrier
function [85-87]. Following the uptake of antigen, DCs shuttle microbes to regional
lymphoid tissue, such as PPs, and present antigen to naïve T lymphocytes to generate
Th1, Th2, or Th17 responses [64]. Though Th1 and Th2 lymphocytes have long been
recognized as vital components of the adaptive immune system [62, 63] and have been
studied in a variety of injury and inflammatory conditions, Th17 lymphocytes remain
vastly unexplored. In regards to gut immunity, Th17 lymphocytes have long been
implicated in both forms of IBD, Chron’s disease and ulcerative colitis [76-78]. Given
their central role in mediating gut mucosal immunity and barrier function, Th17
lymphocytes should be explored in the context of injury, such as EtOH intoxication and
burn.
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Recent data suggest that IL-23, a pro-inflammatory cytokine secreted
predominantly by DCs, is critical for the differentiation of Th17 lymphocytes [31-34]. IL23, a heterodimeric cytokine and member of the IL-12 family, plays a critical role in the
development, expansion and survival of Th17 lymphocytes [31-33, 67, 88]. Binding of
IL-23 to its receptor complex, IL-12Rβ1 and IL-23R, on differentiating T helper
lymphocytes activates STAT3 to maintain upregulation of transcription factor ROR-γt,
which is indispensable in the production and secretion of Th17 effector cytokines IL-17
and IL-22 (Figure 1) [89-93].
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Regulation of Th17 Development and IL-17/IL-22 Production
The development of Th17 cells has been extensively studied and reviewed in mice
and humans [35-37, 68]. Murine models demonstrate that Th17 lymphocytes begin
differentiation under the control of TGF-β and IL-6 [91-93]. Alone TGF-β, induces the
expression of Foxp3 and differentiation of Tregs. However, IL-6 induces the expression
of IL-21 in a STAT3 dependent manner [94]. Subsequently, IL-21, along with IL-6 and
TGF-β, further amplifies STAT3 activation and prompts downstream expression of RORγt [67, 88, 95]. In this manner, IL-21 acts in an autocrine loop on differentiating Th17
cells, similar to the actions of interferon (IFN)-γ and IL-4 on Th1 and Th2 cells,
respectively [88, 94, 96]. IL-21 has further been suggested to exert its actions by inducing
expression of the IL-23 receptor (IL-23R) [67, 88, 95] and suppressing Foxp3 expression
[94, 96]. Lastly, IL-23 expands and stabilizes Th17 cells through further activation of
STAT3 driven ROR-γt expression and subsequent production of Th17 effector cytokines
IL-17 and IL-22 (Figure 1) [31-33, 89].
IL-23, a member of the IL-12 family, is composed of the p19 and p40 subunits;
the p40 subunit is shared by IL-12 while the p19 subunit is unique to IL-23 [34, 97]. IL23 is synthesized and produced by a variety of cells, including DC and Mϕ [34, 97].
Binding of IL-23 to its receptor complex, IL-12Rβ1 and IL-23R, results in Jak2-mediated
phosphorylation of tyrosine residues on the cytoplasmic domain of the IL-23R subunit
[43]. While 12Rβ1 is also part of the IL-12 receptor, IL-23R is unique to the IL-23
receptor complex. Phosphorylated tyrosine residues serve as docking sites for the STAT3
proteins, which in turn become phosphorylated [43]. Once phosphorylated, STAT3
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proteins homodimerize and translocate to the nucleus to upregulate downstream signaling
pathways, including the expression of Th17 hallmark transcription factor ROR-γt [43, 67,
88, 95, 98].
Recently, hypoxia-inducible factor (HIF)-1 was implicated in the regulation of
Th17 differentiation [99]. HIF-1 regulates the metabolic switch from oxidative
phosphorylation to aerobic glycolysis during hypoxic conditions [100], and is a target
gene of activated STAT3 [98]. Dang et al. found increased HIF-1 expression in Th17
cells and demonstrated that naïve T cells from CD4+ specific HIF-1-/- mice failed to
differentiate into IL-17 expressing cells or upregulate mRNA expression of IL-17 and IL23R [99]. Further experimentation revealed that HIF-1 is necessary for STAT3 dependent
expression of ROR-γt and that CD4+ specific HIF-1-/- mice are resistant to experimental
autoimmune encephalitis, a Th17 dependent process. Together, in vitro and in vivo data
supported a role for HIF-1 in modulation of Th17 cells. Chromatin immunoprecipitation
analysis of the ROR-γt binding site on the IL-17 promoter region showed localized
binding of ROR-γt, HIF-1 and transcription factor p300, which modulates HIF-1
mediated gene expression [99]. Collectively, these results demonstrate that Th17
differentiation is regulated by changes in cellular metabolism, including hypoxia.
Given their role in maintaining mucosal immunity, it is not surprising that recent
investigation suggest that Th17 cells may be regulated in the gut through host-commensal
bacteria interactions [101-103]. Ivanov et al. took advantage of ROR-γtgfp/+ mice to
demonstrate that after birth TCRβ+CD4+IL-17+GFP+ cells appear in the small intestine
lamina propria at day 25, and eventually represent the majority of IL-17 producing cells
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by day 33 [102]. These data suggest that the presence of Th17 cells depends on
colonization of the intestine with commensal bacteria. This notion is further supported by
results indicating that germ-free mice, which are devoid of bacteria and fungi, lack Th17
cells. Colonization of germ-free mice with fecal homogenates from control mice induced
Th17 cells in the gut lamina propria within two weeks after colonization [102]. Treatment
of control mice with antibiotics known to affect commensal bacteria diminished the
frequency of Th17 cells in the lamina propria. Through analysis of commensal bacteria
from Th17 sufficient mice, the authors concluded that the presence of Th17 cells in small
intestine lamina propria correlated with the quantity of Gram-negative cytophagaflavobacter-bacteroidetes (CFB) bacteria present in the gut [102]. This group later
demonstrated that colonization of germ-free mice with segmented filamentous bacteria
(SFB), Gram-positive spore-forming bacteria, also induced IL-17 and IL-22 producing
Th17 cells in the gut lamina propria [101]. Wu et al. demonstrated that gut colonization
of mice with enterotoxigenic B. fragilis induced expression of IL-17 in a STAT3
dependent manner [104]. Increased IL-17 was not seen with nontoxigenic B. fragilis or in
CD4 STAT3-KO mice [104]. Together, these data highlight the role of host-commensal
bacteria interactions in regulation of immune homeostasis. Moreover, the duodenum,
through upregulation of Th17 chemokine CCL20, has recently been implicated in the
regulation of Th17 immune cells. In a murine model of Staphylococcus aureus (S.
aureus) sepsis, Esplugues et al. reported increased Th17 cells in the duodenum of S.
aureus treated mice 3 days post bacterial injection, which was not noted in the spleen
[105]. Further analysis of duodenal Th17 cells revealed that these cells exhibited a
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suppressive phenotype, as marked by increased expression of IL-10 [105]. While the
mechanism by which these Th17 cells acquire a suppressive phenotype remains to be
elucidated, these data suggest that the gut is critical in maintaining equilibrium of Th17
cells, which are necessary to clear infection, but are immunopathogenic in excess.
Most recently, the aryl hydrocarbon receptor (AhR) has been implicated in Th17
immunity, particularly in the regulation of IL-22 [44, 45, 106-108]. AhR is a ubiquitous
transcription factor found in the cytoplasm of vertebrate cells. Upon ligand-binding, AhR
translocates to the nucleus where it regulates gene expression. Ligands for AhR include
dioxin and natural chemicals, including bacterial metabolites, derivatives of tryptophan
and phytochemicals. Initially, Veldhoen et al. found selective expression of AhR in
mouse and human Th17 cells, as compared to other T helper cells and further
demonstrated that addition of 6-formylindolo[3,2-b]carbazole (FICZ), a high affinity
ligand of AhR, greatly increased expression of IL-17 and IL-22 in vitro [106]. Moreover,
AhR-/- T cells failed to respond to FICZ treatment, while retroviral transduction of AhR
restored IL-22 expression [106]. Quintana et al. provided evidence suggesting that AhR
controls Th17 differentiation in a ligand dependent manner. In these experiments, in vivo
activation of AhR by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) reduced the frequency
of IL-17+CD4+ cells, and induced the frequency of TGF-β secreting CD4+Foxp3+ Tregs,
which were capable of attenuating experimental autoimmune encephalomyelitis (EAE)
[108]. In line with Veldhoen et al., in vivo activation of AhR by FICZ boosted Th17 cell
differentiation and exacerbated EAE [108].
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As AhR drew attention in the field of Th17 immunity, more recent studies
revealed that AhR plays a greater role in the modulation of IL-22, than IL-17 [44, 45,
107]. Two groups simultaneously demonstrated a subset of human T helper cells that
produce IL-22 but neither IL-17 nor IFN-γ, namely, Th22 cells [44, 45]. Both
demonstrated a vital role for AhR; however, these groups presented conflicting data
regarding the role of ROR-γt in Th22 production of IL-22. Duhen et al. reported low
expression of RORC (ROR-γt in humans) in their Th22 population and concluded that
RORC is non-essential for Th22 development [44]. The authors further showed that de
novo induction of Th22 cells required IL-6 and tumor necrosis factor-α. Conversely,
Trifari et al. used siRNA to demonstrate that silencing of RORC or AhR diminished IL22 production from memory CD4+ T cells, while IL-17 was only affected by silencing of
RORC [45]. This group found that IL-1β and IL-23 are required for de novo induction of
Th22 cells, while the presence of TGF-β induced IL-17 production [45]. The authors
confirmed that FICZ treatment increases IL-22 production, yet provided protein and
mRNA data suggesting that FICZ decreases IL-17 [45], which challenges data by
Veldhoen et al. A third group, further confirmed increased IL-22 and decreased IL-17 in
response to FICZ treatment, but also reported increased IL-22 following TCDD
treatment, which Quintana et al. had demonstrated inhibits IL-17 but did not assess its
effect on IL-22 [107]. Collectively, the consistent data demonstrating a role for AhR in
expression of IL-22 and the discrepancies in the requirements for RORC and effect of
FICZ/TCDD on IL-17 production support the notion that the requirements for IL-22 and
IL-17 production are distinct. Regardless, of whether IL-22 and IL-17 are produced by
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one cell type, Th17 cells, or two cell types, Th17 and Th22, further studies exploring the
molecular mechanism by which AhR regulates IL-22 production are warranted.
There a multiple mechanisms by which AhR may control IL-22. One such
possible mechanism is the interaction between STAT molecules and AhR, where STAT1
and STAT5 have been co-immunoprecipitated with AhR [109]. It is possible AhR and
STAT3 interact to differentially regulated ROR-γt and expression of IL-17 and IL-22.
Most recently, AhR induced Notch signaling has been implicated in the development of
gut IL-22 producing innate lymphoid cells (ILC22), including natural killer (NK)p46 and
lymphoid tissue-inducer (LTi) cells, as well as in the formation of postnatal lymphoid
tissues [110]. While these data focus on innate producers of IL-22, the mechanisms
involved may affect the development of adaptive IL-22 producing T helper cells as well
as the secondary lymphoid tissues necessary for the differentiation of Th17 cells. In line
with previous literature, Lee et al. found reduced production of IL-22 in gut related
lymphoid organs and impaired response to C. rodentium infection in AhR-/- mice [110].
The authors also noted decreased ILCC22 cells and the lack of cryptopatches and isolated
lymphoid follicles in the small intestines of AhR-/- mice, which they attributed to the
absence of AhR signaling. Administration of TCDD induced expression of Notch1 and
Notch2, which was absent in AhR-/- mice [110]. Moreover, mice lacking expression of
RBP-Jκ, the DNA-binding protein that associates with the intracellular regions of all
Notch molecules to mediate transcriptional activity of Notch, demonstrated less ILCC22
cells, as compared to wild-type mice [110]. Together these data suggest that the
development of ILCC22 cells is regulated by AhR mediated Notch activity, a mechanism
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which may also be involved in the adaptive immune response. Further studies should test
the role of AhR and Notch in Th17 cell development as well as establish whether AhR
signaling produces differential immune responses when activated by endogenous versus
exogenous ligands.
Th17 Cells, Ethanol and Burn Injury
While the role of Th17 lymphocytes has been extensively studied in the context of
regulating infection, little work has focused on these cells in the context of injury.
Following traumatic injury, such as burn, there are global changes to the systemic
immune response, including immunosuppression and increased susceptibility to infection.
Traumatic injury, including burn, outcomes are further confounded by the presence of
EtOH intoxication, which is associated with increased susceptibility to infection and
mortality [12, 14-19, 49-51, 53, 111-115]. Burn trauma, regardless of EtOH exposure, is
associated with remote organ injury, affecting the lung [116, 117], kidney [118-120], gut
[61, 121-124] and bone marrow compartment [125-127] in human and animal studies.
Alteration in gut barrier function may facilitate the translocation of gut derived bacteria,
and/or their products, and contribute to the development of sepsis, systemic inflammatory
response syndrome and multiple organ dysfunction syndrome in critically-ill burn
patients [61, 123, 128]. Thus, it is imperative to investigate the interrelationship between
EtOH, burn, remote organ injury and immune suppression. Given their central role in
mediating mucosal immunity, including the gut and lungs, Th17 lymphocytes may play a
role in immune perturbations following EtOH intoxication and burn injury burn injury.
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Murine models of burn injury demonstrate that Th17 responses are elicited by burn
injury. At the site of burn injury, Th17 cytokines IL-17 and IL-22 have been shown to be
elevated ~3-fold as compared to sham injury, within 3 hours of burn in the absence of
significant changes in IL-6, IL-23 or transforming growth factor (TGF)-β [129]. While
these changes are transient, an early perturbation of IL-17 and IL-22 post burn injury may
disrupt the wound healing process and promote burn wound sepsis [130]. Moreover,
heightened IL-17 has been observed at distant sites and in the systemic circulation. IL-17
is elevated in cardiac tissue 3 hours post burn injury [131] and in the circulation one and
seven days post injury [132]. Together these data indicate that local and systemic Th17
immune responses are elicited early on post burn injury, and that sustained elevations in
levels of IL-17 may contribute to the burn induced inflammatory response and
subsequent immune aberrancies.
In the lung, Oppeltz et al. used cells isolated from bronchoalveolar lavage fluid 7
days post burn injury to show heightened IL-17 production following stimulation with
TLR2 agonist zymosan [133]. While this study did not suggest a specific source for IL17, nor identify a cell type responsive to zymosan, it further highlights the importance of
IL-17 at mucosal barriers, such as the lung, and provides reason to investigate the role of
Th17 cells, and their immunomodulatory products, in acute lung injury following burn. In
regards to the effects of EtOH on Th17 immunity in the lung, Shellito et al. found
increased mortality and decreased IL-17/myeloperoxidase (MPO) levels in response to
pulmonary K. penumoniae inoculation following 2-weeks of 20% EtOH consumption
[134]. These results were further substantiated when local delivery of the IL-17 gene

21
improved mortality and restored pulmonary MPO levels following chronic EtOH feeding
and K. pneumoniae inoculation [134]. A more recent study utilized a single dose of EtOH
and pulmonary K. pneumoniae infection model to demonstrate that EtOH suppresses
mRNA expression of IL-23 in the lung following pulmonary infection [135]; thus,
suggesting a role for APCs in impaired Th17 immunity. Happel et al. confirmed their
findings by demonstrating that EtOH inhibits the mRNA expression of IL-23 in alveolar
macrophages stimulated directly with K. pneumoniae in a dose-dependent manner[135].
At the protein level, a dose-dependent decrease in splenocyte IL-17 production was
elicited by supernatants from EtOH treated alveolar macrophages [135]. Perturbation of
Th17 immunity may be exacerbated following combined EtOH exposure and burn injury,
which may result in host immunosuppression and susceptibility to infection.
Other experimental models of burn injury demonstrate bimodal skewing of Th17
lymphocytes. Neely et al. reported increased Th17 cells (IL-17+CD4+) 3 and 14 days post
burn injury in draining peripheral lymph nodes, but not spleens of injured mice [136].
More importantly, this group demonstrated a decreased Th17/Th1 ratio day 3 post injury,
which normalized at day 7 and increased at day 14 [136]. Early post burn injury, a
decreased Th17/Th1 ratio may contribute to increased susceptibility to extracellular
pathogens, including K. pneumoniae and C. albicans. Conversely, late post burn injury,
an increased Th17/Th1 ratio may perturb Th1 dependent immune responses.
Patient data specific to the Th17 axis following burn injury, and its possible role
in remote organ damage, is quite limited. However, data from the Inflammation and Host
Response Glue Grant indicate that serum IL-17 is elevated in adult and pediatric burn
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patients within one week post injury [137, 138]. Heightened levels of IL-17 are
exacerbated in pediatric as compared to adult patients [137], suggesting an age dependent
difference to burn injury, which may play a role in the development of a hypermetabolic
state. Recently a single center study examined Th17 cell development in 26 burn patients
with third-degree thermal injuries. The results revealed that peripheral blood
mononuclear cells isolated from these patients had a decreased ability to express ROR-γt
and produce IL-17 in response to TCR activation and C. albicans challenge, which has
been shown to increase mortality in burn patients [139, 140]. Inatsu et al. further reported
measureable levels of IL-10 in sera from burn patients, and demonstrated an inhibitory
role for IL-10 in the development of CD4+ROR-γt+ IL-17 producing T cells [139].
Though the molecular mechanism by which burn injury induced IL-10 inhibits IL-17
remains to be elucidated, this study highlights the perturbation of Th17 cells following
burn injury and warrants further investigation in the context of traumatic injury, including
burn. In the context of EtOH, human PBMCs demonstrate impaired expression of Th17
transcription factor ROR-γt, as well as decreased frequency of IL-17 producing CD4+ T
cells [141]. Conversely, EtOH treatment increased expression of T reg transcription
factor Foxp3 [141], suggesting a skew towards a T reg phenotype [142]. Thus,
suppression of antigen specific Th17 responses, following EtOH and/or burn injury, may
lead to increased susceptibility to bacterial and fungal infection, particularly at mucosal
interfaces, including the lungs and gut. Studies focusing on the role of the Th17 axis
following EtOH exposure, burn and other traumatic injury are necessary to define the
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normal temporal dependent Th17 responses to injury and to identify whether these
changes contribute to remote organ damage, susceptibility to infection and mortality.
Given the limited literature on Th17 cells in response to EtOH and/or burn
trauma, the role of Th17 cells in clinical sepsis was reviewed. To date, no direct
perturbations of CD3+CD4+ lymphocyte derived IL-17 have been reported in clinical data
or experimental models of sepsis. However, Flierl et al. did show increased IL-17 in a
murine model of cecal ligation and puncture (CLP), though this was attributed to γδ T
cells, not CD3+ αβ T cells [143]. Moreover, the authors demonstrated that neutralization
of IL-17 correlated with decreased bacteremia, increased survival and decreased plasma
levels of pro-inflammatory cytokines TNF-α, IL-1β and IL-6 [143]. Together these data
suggest that γδ T cell derived IL-17 negatively impacts outcomes from sepsis, through
modulation of pro-inflammatory cytokines [143]. This observation was confirmed when
γδ T cell knockout mice showed improved survival and decreased plasma IL-17
following CLP [143]. More recently, these findings were substantiated when the same
laboratory took advantage of Rag-1 knockout mice, which lack T and B cells, to
demonstrate that lack of CD3+ T cells does not affect outcome of severe sepsis following
CLP [144], again eliminated the role of CD3+ Th17 cells.
IL-22, the other major immunomodulatory secretory product of Th17 cells, has
also been shown to negatively affect outcomes during septic injury. While IL-22 is
generally considered a protective cytokine, models of peritonitis, as well as clinical data
from patients with abdominal sepsis suggest that higher levels of IL-22 may facilitate
bacterial burden and septic complications. Specifically, Weber et al. demonstrated
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increased levels of IL-22 in kidney and spleen following CLP peritonitis [145]. Inhibition
of IL-22 following CLP enhanced bacterial clearance, promoted phagocyte recruitment,
attenuated organ dysfunction and decreased expression of IL-10 [145]. Similarly, a rat
model of CLP revealed measureable levels of IL-22 in serum from septic animals [146].
Clinically, a single center hospital study of 16 patients that developed abdominal sepsis
following surgery, demonstrated significant elevations in serum IL-22 as compared to
healthy volunteers and control surgery patients without septic complications [147]. As
compared to control groups, IL-10 was also significantly increased in patients with
abdominal sepsis [147]; again highlighting that IL-22 may modulate IL-10 levels
resulting in heightened bacterial growth [145]. Together these findings indicate an
interdependent relationship between IL-22 and IL-10, which modulates a critical balance
between bacterial burden and host immune/barrier homeostasis. As such, adequate levels
of IL-22 must be maintained to regulate host immune/barrier integrity while higher levels
may induce increased expression of IL-10, subsequently enhancing bacterial growth and
increasing the risk of sepsis. Further studies evaluating this interdependency between IL22, IL-10, bacterial burden and host immune/barrier defense may provide a mechanism
by which these interactions are regulated and lead to the identification of novel
therapeutic targets for patients who develop septic complications.
Protective Role of IL-22: Underlying Mechanism and Therapeutic Potential
The protective and regenerative effects of IL-22 have led to the investigation of
IL-22 as a therapeutic agent, which has produced promising results, particularly in the
field of gastrointestinal related disease. In a model of concanavalin A (ConA)-induced T
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cell-mediated hepatitis, in vivo treatment with IL-22 prevented liver injury, as marked by
increased levels of hepatic enzymes alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) [84]. Conversely, treatment of animals with anti-IL-22 antibody
exacerbated ConA-induced ALT and AST levels [84]. This observation was later
confirmed, when IL-22-/- mice were shown to be more susceptible to ConA-induced
hepatitis than wild-type counterparts [83]. Radaeva et al. further demonstrated a role of
STAT-3 activation in IL-22 dependent modulation of liver injury. Using the human
HepG2 heptoma cell line, IL-22 was shown to inhibit apoptosis through induction of antiapoptotic proteins Bcl-xL, Bcl-2 and Mcl-1 and promote proliferation through activation
of c-myc, cyclin D1 and retinoblastoma (RB) 2 [84]. In vivo, Radaeva et al. injected IL22 transfected or null HepG2 cells into mice, and found that mice injected with IL-22
transfected HepG2 cells developed larger tumors with heightened levels of activated
STAT3, Bcl-xL and Rb2, compared to null HepG2 injected mice [84]. Together, these
results demonstrate a protective role for IL-22 in T cell-mediated liver injury, which is
dependent on activation of STAT3, and subsequent induction of proliferation and
inhibition of apoptosis in hepatocytes, both in vivo and in vitro. To further elucidate the
protective role of IL-22 in ConA-induced hepatitis, Zenewicz et al. injected differentiated
Th17 cells from IL-22-/- or wild-type mice into IL-22-/- mice and found that recipients of
IL-22-/- Th17 cells exhibited higher ALT and AST levels [83]; confirming a protective
role for IL-22 against T cell mediated liver injury.
More recently, the same group demonstrated that treatment with a single dose of
IL-22 attenuates chronic-binge alcohol induced liver injury [47]. Ki et al. used a modified
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Lieber-DeCarli diet and single high dose of ethanol by oral gavage to produce fatty liver
and liver injury, as marked by increased levels of hepatic enzymes ALT and AST,
increased hepatic triglyceride levels and steatosis. Though the authors did not establish
decreased IL-22 in the context of alcohol induced liver injury, their data did demonstrate
increased expression of IL-22R1 in mice and patients with alcoholic hepatitis [47]. Thus,
IL-22 may be required for normal liver homeostasis and, in the presence of alcohol, the
IL-22 pool may not be sufficient for normal hepatic functions. Ki et al. found that IL-22
treatment prevented alcohol induced elevations in serum AST/ALT and hepatic
triglyceride levels and steatosis. The authors attributed the protective effect of IL-22 to
induction of liver antimicrobial lipocalin 2 and the antioxidant gene metalothione as well
as decreased expression of a fatty acid transport protein, though modulation by STAT3
was variable [47]. These results were later confirmed using liver specific IL-22
transgenic (IL-22TG) mice, which proved resistant to ConA-induced T cell hepatitis
[148]. IL-22TG mice also recapitulated upregulation of anti-oxidant and mitogenic genes
noted with exogenous IL-22 treatment [148]. Collectively, these data highlight the
antioxidant, antisteatotic and antimicrobial effects of IL-22 and elucidate a possible role
for IL-22 in the treatment of alcoholic liver disease.
Most recently, IL-22 was proposed to modulate pancreatitis through regulation of
autophagy related proteins [149]. In a mouse model of cerulein-induced pancreatitis, IL22KO and IL-22TG mice were utilized to elucidate the vital role of IL-22 in mediating
pancreatic injury and function. IL-22KO mice demonstrated a similar phenotype as wildtype mice in response to acute and chronic cerulein injections; both strains had increased
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pancreatic weight to body weight ratios, amylase, lipase, MPO cells infiltration and
apoptosis [149]. Knocking out of IL-22 did not exacerbate injury. Moreover, liver
specific overexpression of IL-22, in IL-22TG mice, showed no pathologic response to
cerulein treatment [149]. The potential role for IL-22 as a possible therapeutic option for
the treatment of pancreatitis was further highlighted when treatment of wild-type animals
with IL-22, prior to acute cerulein injection, also ameliorated changes in amylase, lipase
and inflammatory cell infiltration. Similarly, IL-22 treatment via adenoviral delivery
ameliorated chronic cerulein-induced pancreatitis [149]. As previously mentioned, IL-22
inhibits apoptosis through activation of anti-apoptotic genes, including Bcl-2 and Bcl-xL.
To dissect the mechanism by which IL-22 modulates the development of pancreatitis,
Feng et al. tested the role of Bcl-2 and Bcl-xL in the regulation of autophagy, which has
been implicated in the progression of pancreatitis [150]. Moreover, Bcl-2 proteins inhibit
Beclin-1 dependent autophagy [151]. In line with these finding, cerulein-treated IL-22TG
mice had decreased formation of autophagosomes as compared to wild-type counterparts
[149]. Feng et al. further showed that IL-22TG mice displayed increased Bcl-2/Bcl-xL
and Beclin-1 interactions, as compared to wild-type mice [149], suggesting a role for IL22 mediated induction of Bcl-2/Bcl-xL and Beclin-1 interactions, which inhibit
pancreatic pathology and autophagy.
Studies of IBD consistently emphasize the role of Th17 cells in the pathogenesis
of ulcerative colitis and Chron’s disease [68, 152]. Yet, most of these studies highlight
the role of IL-17, and pay less regard to IL-22. Zenewicz et al. eloquently explored the
role of IL-22 in IBD by taking advantage of B and T cell null Rag1-/- (lack T cells) and
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IL-22 mice. Rag1 mice lack T cells, including regulatory T cells; thus, when naïve
CD4+ T cells from wild-type mice are adoptively transferred to Rag1-/- mice, they rapidly
expand and acquire effector functions in an uncontrolled manner causing the
development of massive inflammation in the gut, similar to that found with IBD. These
adoptive transfer studies revealed increased colitis and colonic levels of IFN-γ, IL-17 and
IL-22 as well as weight loss, as compared Rag1-/- mice that did not receive T cells [153].
To clarify the role of IL-22 in intestinal colitis, IL-22-/-Rag1-/- mice were injected with
naïve CD4+ T cells from IL-22-/- or wild type mice. Both treatments resulted in the
development of colitis, yet IL-22-/-Rag1-/- mice injected with naïve T cells from IL-22-/donor mice demonstrated more severe colitis and weight loss than mice that received
wild-type T cells [153]; suggesting a protective role for IL-22 producing cells in the
development of gut inflammation. Interestingly, Rag1-/- mice injected with T cells from
IL-22-/- donors, demonstrated the same expression of IL-22 as IL-22-/-Rag1-/- mice that
received T cells from wild type mice [153], indicating a host derived source of IL-22.
Further analysis revealed that innate NK cells are a major contributor of IL-22 in the gut.
This graded response, in which abolishment of IL-22 in recipient mice and donor T cells,
as compared either alone, produced increasingly worse colitis and weight loss
convincingly indicates that IL-22 plays a role in the development of gut inflammation. To
further underscore the protective role of IL-22, Zenewicz et al. utilized a model of innate
colitis, dextran sodium sulfate (DSS)-induced colitis, which causes disruption of colonic
epithelial integrity and subsequent inflammation and colitis. IL-22-/- mice treated with
DSS lost significantly more weight and exhibited greater mortality than DSS treated
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wild-type mice [153]; confirming the protective role of IL-22. In yet another model of
intestinal colitis, Sugimoto et al. used IL-22 gene delivery in a murine model of Th2mediated colitis. Their results indicate that IL-22 treatment increased goblet cell
expression and reduced colonic diameter and thickness in a STAT3 dependent manner
[154]. These results were extended in a DSS model of colitis, where peak levels of
colonic IL-22 correlated with increased production of membrane bound mucins (Muc1, 3, -10 and -13) during the recovery phase of DSS colitis [154]. IL-22 failed to modulate
colitis in mice treated with a mucolytic agent, which removes the colonic mucus layer,
blocking the actions of IL-22 on mucin production. Similarly, mice concurrently treated
with IL-22 neutralizing antibody and IL-22 exhibited greater weight loss, decreased
STAT3 activation and decreased goblet cell accumulation as compared to mice treated
with control antibody and IL-22 [154], confirming that IL-22 restores goblet cells in a
STAT3 dependent manner.
These studies demonstrating the protective role of IL-22 in liver, pancreas and
intestinal tract provide promising evidence for the use of IL-22 in the treatment of
gastrointestinal related disease, which may be extended to gut pathology induced by
injury, including EtOH and/or burn trauma. The early animal studies provide a strong
foundation and offer a unique challenge to translation research teams. At the bench,
studies exploring whether IL-22, IL-22R and/or its signaling pathway is perturbed in
patients with gut related pathologies, may reveal epigenetic changes or genetic
polymorphisms specific to patients who develop disease or remote organ damage
following EtOH and burn. These findings would help advance the treatment of disease
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through the development of new therapeutic agents, as well as through modulation of
gene expression with gene therapy. Clinically, research exploring the possibility of
treating patients with recombinant IL-22 should be considered in patients with severe
gastrointestinal disease who have failed standard therapy. Results from these studies
would give a better understanding of the short and long term effects of IL-22 and help
redirect related basic research. Lastly, investigation of IL-22 as a therapeutic agent may
prove beneficial in the treatment of critically-ill patients who sustain secondary organ
damage, such as burn and trauma patients.
Significance
EtOH intoxication prior to injury augments post burn pathogenesis [2-6, 11-13],
yet the mechanisms by which this occurs remain largely unexplored. Gut barrier
dysfunction is frequently associated with ethanol exposure and major injury. Our
laboratory has previously demonstrated that acute EtOH exposure prior to burn injury is
associated with intestinal T cell suppression and increased bacterial translocation [14-21].
Th17 lymphocytes maintain intestinal immune homeostasis and barrier function [22-25,
39, 85, 86]. Th17 cells are now well established modulators of immune and host
epithelial homeostasis, particularly at host/environment interfaces. While ROR-γt
remains the hallmark Th17 transcription factor, new data scrutinizing the regulation of
Th17 effector cytokines IL-17 and IL-22 propose complex networks involving metabolic
changes, host/commensal bacteria interactions and environmentally or endogenously
derived chemicals in the maintenance of proper Th17 balance. Where impaired Th17
responses diminish bacterial clearance and increase epithelial vulnerability, uncontrolled

31
Th17 effector functions promote autoimmune disease. Thus, the multiple pathways
regulating Th17 immunity are interdependent and must be tightly regulated. Injuries,
such as burn, trauma and clinical sepsis have global systemic consequences, many of
which affect the delicate mechanisms that govern Th17 immunity. Suppression of antigen
specific Th17 responses, as noted with burn injury, may contribute to infection, remote
organ damage and mortality. Given the importance of this emerging subset, the role of
Th17 cells following clinically relevant host injury remains relatively unexplored and
warrants deeper investigation.

CHAPTER THREE
ETHANOL EXPOSURE SUPPRESSES BONE MARROW-DERIVED DENDRITIC
CELL INFLAMMATORY RESPONSES INDEPENDENT OF TLR4 EXPRESSION
Abstract
Acute alcohol (ethanol) exposure is linked with increased susceptibility to
infection and increased mortality in trauma and burn patients. Dendritic cells (DCs) are
central mediators in innate and adaptive immune responses, and play a role in
presentation of pathogens to adaptive immune cells. We investigated the effects of acute
ethanol exposure on bone marrow-derived dendritic cell (BM-DC) responses. Total bone
marrow cells, obtained from 8-10wk old C57BL/6 male mice, were cultured in the
presence of GM-CSF and IL-4 for 7 days. BM-DCs were harvested and treated with
increasing doses of ethanol (50, 100 and 250 mM) at the time of, or 3 hours prior to,
lipopolysaccharide (LPS). Following LPS, supernatants were collected for cytokine
measurement and cells were harvested for flow cytometry. Concurrent acute ethanol
exposure and LPS treatment resulted in a dose-dependent suppression of IL-6, IL-12p40,
IL-23 and IL-10. Additionally, ethanol exposure prior to LPS, dysregulated the IL12p40/IL-23 balance and more profoundly suppressed IL-6 and IL-10 secretion by BMDCs, as compared with cells treated concurrently with ethanol and LPS. Ethanol
treatment did not affect toll-like receptor (TLR)4 or TLR2 expression. In summary, our
study demonstrates that acute ethanol exposure suppresses BM-DC LPS-induced
responses irrespective of affecting TLR4 or TLR2 expression.
32
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Introduction
Numerous bodies of literature indicate that acute and chronic ethanol
consumption lead to aberrant immune responses to bacterial and viral pathogens [6, 155,
156]. Specifically, acute ethanol exposure results in increased infectious complications
following trauma and burn [4, 6, 157]. In vivo and in vitro studies further demonstrate
that acute ethanol exposure downregulates lipopolysaccharide (LPS)-induced immune
responses, including reduced production of tumor necrosis factor (TNF)-α, interleukin
(IL)-1β and IL-6 from murine and human macrophages and monocytes [113, 114, 158162]. Closely related to macrophages, dendritic cells (DCs) are a subset of antigen
presenting cells (APCs) that arise from myeloid precursors [163]. Despite the
overwhelming amount of evidence indicating ethanol as an immunomodulatory agent in
LPS-induced macrophage responses, only a small number of studies have examined the
effects of ethanol on LPS-mediated DC immune responses [164-167].
DCs comprise a migratory group of bone marrow-derived leukocytes which are
able to uptake, transport, process and present antigen [168-170]. Following uptake of
antigen, DCs migrate from the periphery to draining lymph nodes and undergo
maturation, marked by increased expression of major histocompatibility complex (MHC)
Class II and other genes that promote antigen presentation. In secondary lymphoid
organs, DCs present antigen via MHC II to naïve T lymphocytes to generate T helper
(Th)-1, Th-2 or Th-17 responses [64]. Thus, in their role as APCs, DCs are a critical link
between the innate and adaptive arms of the immune system.
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Like monocytes/macrophages, DCs express various pattern recognition receptors,
including toll like receptors (TLRs). Receptor ligation of TLRs by specific ligands
induces various signaling pathways to modulate immune responses. Specifically, LPS
activates immune cells through its interaction with TLR4 [171], which results in
activation of multiple downstream signaling pathways and transcription factors, including
the MyD88-dependent and mitogen activated protein kinase (MAPK) pathways [171].
Ultimately, this leads to the release of multiple cytokines, including TNF-α, IL-1, IL-6,
IL-10, IL-12 and, most recently, IL-23, which is known to be a critical mediator of Th-17
polarization [113, 114, 172-177].
Currently, the literature addressing the effects of ethanol exposure on DC immune
responses is quite limited, particularly in the context of acute ethanol exposure. To date,
the effects of acute ethanol exposure on DC function are limited to DCs derived from
monocytes isolated from healthy human donors exposed to ethanol prior to venipuncture
[164, 178]. These studies demonstrate that DCs derived from volunteers exposed to
ethanol had decreased expression of co-stimulatory molecules CD80 and CD86, which
are required for T cell activation [164]. Functionally, DCs from ethanol exposed
volunteers induced T cell anergy, inhibited Th1 activation and resulted in decreased T
cell proliferation [164, 178]. In line with published literature on monocytes and
macrophages, these studies showed decreased secretion of Th1 polarizing IL-12 and
increased secretion of anti-inflammatory IL-10 [164]. Similarly, Lau et al. demonstrate
that acute ethanol exposure inhibited differentiation of BM-DC, subsequent co-signaling
molecule expression, naïve T cell activation and impaired production of IL12p70 [165].
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Murine models of chronic ethanol abuse demonstrate that chronic ethanol consumption
suppressed the ability of DCs to stimulate activation and proliferation of naïve T cells,
both in vivo and in vitro [165-167]. In regards to cytokine production, DCs from ethanolfed mice produced less IL-12p40, TNF-α and IFN-α [167]. These data provide evidence
to suggest that ethanol exposure results in aberrant DC immune responses, which may
result in an imbalanced immune response and detrimental outcomes following infection
or trauma. However, the effects of acute ethanol exposure on differentiated DCs remain
to be elucidated.
To explore the impact of acute ethanol on DC cytokine production, our study
utilized bone marrow-derived dendritic cells (BM-DCs) to evaluate the concurrent and
pre-treatment, as well as dose-dependent, effects of ethanol on DC cytokines known to
mediate T cell responses, IL-12p40, IL-6, IL-23 and IL-10. Using differentiated DCs and
LPS, our study models a scenario in which the host is immunologically challenged while
under the influence of ethanol intoxication. Thus, our study directly measures the effects
of acute ethanol exposure on differentiated DCs, rather than exploring the effects of
ethanol on DC differentiation. We also sought to determine if TLR expression contributes
to ethanol-mediated cytokine dysregulation. Herein, we show that acute ethanol exposure
results in a dose-dependent perturbation of IL-6, IL-12p40, IL-23 and IL-10. Moreover,
our data suggest that acute ethanol exposure has more profound effects if DCs are pretreated with ethanol than if they are exposed to ethanol at the time of LPS stimulation.
Lastly, we demonstrate that acute ethanol exposure blunts LPS-induced cytokine
responses independent of TLR4 or TLR2 expression.
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Materials and Methods
Animals
Male C57BL/6 mice (Harlan Laboratories), 8-9 week old, weighing 22-25 g, were
used in the experiments. Animals were allowed to acclimate to the animal facility for 2
weeks before being used for experiments. All experiments were conducted in accordance
with the guidelines set forth in the Animal Welfare Act and were approved by the
Institutional Animal Care and Use Committee at the Loyola University Chicago Health
Sciences Division.
Bone Marrow Isolation and DC Differentiation
BM-DCs were generated in vitro from total bone marrow, as previously described
[179-181]. Briefly, femurs and tibias were dissected from unmanipulated mice. Both ends
of each bone were cut open and bone marrow flushed out with 3 ml cold RPMI-1640
medium (Thermo Fisher Scientific) using a 22 gauge needle. Subsequently, bone marrow
was brought to single cell suspension by pipetting and passage through a 70 µm cell
strainer. Total bone marrow cells were counted by hemocytometer, washed in RPMI
medium, adjusted to a concentration of 2 x 106 cells/ml. Bone marrow cells, 10 x 106
cells, were cultured in complete RPMI-1640 supplemented with 2 mM L-glutamine, 50
µM 2-mercaptoethanol, 10 mM HEPES, 50 µg/ml gentamicin, 100 U/ml penicillin, 100
µg/ml streptomycin, 10% heat-inactivated FCS (Thermo Fisher Scientific), 50 ng/ml
granulocyte/monocyte-colony stimulating factor (GM-CSF, R&D Systems) and 100 U/ml
IL-4 (R&D Systems) in 100-mm tissue culture dishes at 37oC and 5% CO2 for 7-10 days.
Every 3 days, cell cultures were washed and media replaced with complete RPMI-1640
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containing GM-CSF and IL-4. On days 7-10, BM-DC were harvested using Accutase
detachment medium (eBioscience), washed, counted by hemocytometer and resuspended
in complete RPMI-1640 medium at a concentration of 2 x 106 cells/ml. The purity of DCs
by co-expression of CD11c and MHC II was assessed via FACS analysis as described
below.
Ethanol Exposure and LPS stimulation in vitro
Following differentiation, BM-DC (2 x 105 cells/well) were cultured in the
presence of increasing doses of ethanol (0, 50, 100 and 250 mM) for either 3 hours prior
to, or in parallel with, LPS (1µg/ml) stimulation in 96-well plates at 37°C and 5% CO2
for 24 h in a humidified chamber. Following ethanol exposure and LPS stimulation, cell
supernatants were harvested for the measurement of IL-6, IL-10, IL-12p40 and IL-23 by
ELISA. Additionally, cells were harvested for measurement of cell viability (see
Appendix A1), TLR4 and TLR2 expression by flow cytometry, as described below.
CD11c, MHC II, TLR2 and TLR4 Expression
Flow cytometric analysis was performed to determine DC purity as well as TLR2
and TLR4 expression following ethanol exposure and LPS stimulation. Briefly, BM-DC
(4 x 105 cells) were collected and resuspended in staining buffer (PBS containing 5%
FCS and 2 mM EDTA). Cell suspensions were blocked with anti-CD16/32 (0.5 µg/100
µL staining buffer) and rat IgG for 20 min at 4°C and subsequently stained with PE
conjugated anti-CD11c (0.25 µg/100 µL staining buffer), FITC conjugated anti-MHC II
(0.25 µg/100 µL staining buffer), PE-Cy7 conjugated anti-TLR4 (0.5 µg/100 µL staining
buffer) and Alexa 647 conjugated anti-TLR2 (0.1 µg/100 µL staining buffer) for 30 min
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at 4°C. Cells were washed twice, resuspended in 500 µL staining buffer and analyzed at
the Loyola University Medical Center FACS Core Facility using a FACSCanto I (BD
Bioscience). All FACS data analyses were performed using FlowJo software (Treestar).
All antibodies used for flow cytometry were purchased from eBioscience.
Cytokine Measurement
Cytokine production in BM-DC cultures was determined by ELISA. The IL-6 and
IL-12p40 ELISAs were purchased from BD Bioscience and the IL-10 and IL-23 ELISAs
were purchased from R&D System. IL-12 and IL-23 are both members of the IL-12
family that share the p40 subunit [31, 32]. Given that we measured IL-23 by an ELISA
kit that does not react with IL-12, we used IL-12p40 as a proxy for IL-12.
Statistical Analysis
Results are presented as mean + standard error of the mean. ANOVA with Tukey
post-hoc testing was used to compare between experimental groups. All statistical
analyses were performed using InStat 3.0 (GraphPad Software). p<0.05 was considered
statistically significant.
Results
DC purity
DCs were differentiated from total bone marrow cells in the presence of GM-CSF
and IL-4, as previously described [180, 181]. Following differentiation, BM-DC purity
was determined based on co-expression of DC markers CD11c and MHC II [87, 179,
182]. Culture of total bone marrow cells with GM-CSF and IL-4 yielded an average of
>90% CD11c+MHC II+ cells (Fig. 2).

39

Figure 2. Representative FACS plots of bone marrow-derived dendritic cell population.
Following 7-10 day culture in complete RPMI media containing GM-CSF (50 ng/ml) and
IL-4 (100 U/ml), cells were harvested and analyzed for expression of dendritic cell
markers, CD11c and MHC II. Cell suspensions were stained with FITC-labeled antiMHC II and PE-labeled CD11c antibodies. A, Live gate on a forward versus side scatter
plot. B, Percentage of total live cells expressing MHC II and CD11c - value represents
mean ± SEM, n=7 animals from two independent experiments.

Ethanol exposure leads to BM-DC cytokine dysregulation
To determine the effect of ethanol exposure on secretion of pro- and antiinflammatory cytokines, BM-DCs were cultured with LPS (1 µg/ml) in the presence of
increasing doses of ethanol (50, 100 and 250 mM) or following 3 hours of ethanol pretreatment at the same doses (Fig. 3). We evaluated IL-12p40, IL-6 and IL-23, three proinflammatory cytokine generated by DCs that are important for Th1 (IL-12) and Th17
(IL-6 and IL-23) polarization. We also examined IL-10, an anti-inflammatory cytokine
associated with a Th2 immune response. Cell viability by flow cytometry, as determined
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by the percent of cells in the live gate, was not affected by ethanol or LPS treatment (see
Appendix A1).
Concurrent treatment of BM-DC with LPS and ethanol led to a dose dependent
decrease in IL-12p40, IL-23 and IL-10 with maximum suppression of IL-6 seen at 50
mM (Fig 3). Introduction of LPS and 50 mM ethanol in parallel resulted in a 25%
decrease in IL-6 secretion from BM-DCs compared with LPS alone (Fig. 3A, p<0.05 for
50 mM ethanol + LPS group as compared with LPS alone). At increasing doses no
additional suppression was seen, though it should be noted that there was no statistical
significance between the three ethanol doses in respect to IL-6 secretion. This ethanol
mediated cytokine suppression was also seen with IL-23 (Fig. 3C, p<0.001 as compared
with LPS alone). Specifically, concurrent addition of LPS and ethanol (50, 100 and 250
mM) resulted in ~ 40%, 55% and 68% reduction of IL-23 release, respectively. In
response to concurrent ethanol exposure and LPS stimulation, IL-12p40 secretion was
decreased as compared with the LPS alone group, but only reached significance when
treated with 250 mM ethanol (Fig. 3B, p<0.05). While 50 mM ethanol treatment
administered simultaneously with LPS did not affect IL-10 secretion, 100 and 250 mM
ethanol exposure plus LPS stimulation resulted in 30% and 75% reductions in IL-10
release, respectively (Fig. 3D, p<0.05 compared with LPS alone). Co-culture with 250
mM ethanol and LPS resulted in a significant decrease in IL-10 release as compared with
co-cultures with 50 and 100 mM ethanol (Fig. 3D, p<0.05). Together these data suggest
that ethanol treatment at the time of immune challenges leads to global BM-DC cytokine
suppression.
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Figure 3. BM-DC cytokine release following ethanol exposure and LPS stimulation. BMDCs (2 x 106 cell/well) were cultured in 96-well plates in the presence of LPS (1 µg/ml)
and varying concentrations of ethanol for 24 hours at 37°C. Supernatants were harvested
for the measurement of IL-6, IL-12p40, IL-23 and IL-10 by ELISA. Values are means +
SEM, n=4-7 animals/group from two independent experiments.*, p<0.05 as compared to
LPS only group; #, p<0.001 as compared to all groups; †, p<0.05 as compared to
corresponding ethanol dose + LPS group; §, p<0.05 as compared to corresponding
ethanol (50 mM) group by ANOVA with Tukey post-hoc test.
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To further elucidate if ethanol exerts differential effects on BM-DC cytokine
secretion following immune stimulation, BM-DCs were pre-treated with ethanol for 3
hours prior to culture with LPS. Pre-treatment of BM-DCs with increasing doses of
ethanol (50, 100 and 250 mM) resulted in ~25%, 40% and 60% IL-6 secretion in
response to LPS, respectively (Fig. 3A, p<0.05, as compared with LPS alone group).
Moreover, pre-treatment of DCs with 250 mM ethanol resulted in a 50% reduction in IL6 release as compared with BM-DCs pre-treated with ethanol 50 mM (p<0.05) and to
DCs concurrently cultured with LPS and ethanol 250 mM (p<0.05). Ethanol treatment
prior to LPS stimulation lead to a marked dose-dependent suppression (~30%, 45% and
75% at 50, 100, and 250 mM ethanol, respectively) of IL-23 as compared with LPS
alone (Fig. 3C, p<0.001). However, this suppression was irrespective of the timing of
ethanol exposure relative to LPS treatment and was most profound in cells exposed to
250 mM ethanol as compared with lower doses (Fig. 3C, p<0.05). While these two
cytokines exhibited a similar, or slightly more extensive, immune suppression with
ethanol pre-treatment, IL-12p40 was paradoxically elevated in supernatants from BMDCs treated with 50 mM ethanol prior to LPS stimulation, as compared with LPS
treatment alone (Fig. 3B, p<0.05). Likewise, compared with BM-DCs treated with 50
mM and 100 mM ethanol in parallel with LPS, IL-12p40 secretion from corresponding
pre-treated cells was significantly elevated (p<0.05). However, pre-treatment of cells
with higher ethanol concentrations (100 mM and 250 mM) did not lead to significant
changes in IL-12p40 production when compared with LPS treatment alone. These data
suggest the ethanol may exert differential effects on the mechanisms that modulate these
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cytokines, and may alter the ability of DCs to effectively induce one T cell subset over
another. Pre-treatment with ethanol also seems to more profoundly impact the ability of
BM-DC to exert immunosuppressive effects. Prior exposure of BM-DCs with 50, 100
and 250 mM ethanol resulted in 60%, 81% and 100% decline in IL-10 release,
respectively (Fig. 3D, p<0.05 as compared with LPS alone). When compared with BMDCs exposed to LPS and ethanol concurrently, ethanol exposure 3 hours prior to LPS
exacerbated suppression of IL-10 secretion. Prior incubation with 50 mM and 100 mM
ethanol diminished IL-10 release by 56% and 73%, as compared with BM-DCs at the
respective doses in the concurrent treatment group (Fig. 3D, p<0.05). Notably, pretreatment of DCs with 250 mM ethanol abolished IL-10 release, whereas co-culture with
ethanol and LPS diminished IL-10 release by 75% (Fig. 3D, p<0.05, as compared with
250 mM EtOH plus LPS group).
Ethanol does not alter BM-DC TLR4 or TLR2 expression
In order to determine whether the difference in cytokine levels with ethanol
exposure were a result of alterations in the receptor for LPS, we used flow cytometry to
analyze expression of TLR4 on BM-DCs (Fig. 4). LPS stimulation resulted in a ~25%
decrease in the percentage of DCs expressing TLR4, as compared with unstimulated cells
(Fig. 4A, p<0.05). Similarly, LPS challenge resulted in a ~50% decrease (p<0.05) in the
mean fluorescence intensity (MFI) of TLR4, as compared with unstimulated cells (Table
1). This reduction in percentage as well as per cell expression of TLR4 expression
(summarized in Table 1) may be due to receptor ligation or internalization. DCs exposed
to ethanol, prior to or at the time of LPS challenge, demonstrated a similar reduction in
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Unstimulated
LPS
Ethanol (50 mM)
+ LPS
Ethanol (100 mM)
+ LPS
Ethanol (250 mM)
+ LPS
Ethanol (50 mM)
3hrs, LPS
Ethanol (100 mM)
3hrs, LPS
Ethanol (250 mM)
3hrs, LPS
Ethanol 50 mM
Ethanol 100 mM
Ethanol 250 mM

TLR4
% CD11c+,
TLR4
+
MHC II ,
Expression
TLR4+
(Fold
Difference)

TLR2
% CD11c+,
TLR2
+
MHC II ,
Expression
TLR2+
(Fold
Difference)

95.77 ± 0.57

27.17 ± 2.21

71.77 ± 7.10 *
77.07 ± 4.80
78.00 ± 4.40
65.48 ± 1.21 *#
77.20 ± 5.17
76.59 ± 5.65
74.40 ± 5.42 *

1.00 ± 0.04
0.52 ± 0.02
**
0.51 ± 0.01
**
0.50 ± 0.01
**
0.49 ± 0.01
**
0.53 ± 0.03
**
0.56 ± 0.05
**
0.50 ± 0.02
**

63.71 ± 6.33 ##
63.93 ± 6.59 ##
60.06 ± 7.83 ##
76.30 ± 1.84 ##
65.56 ± 7.84 ##
59.93 ± 9.65 ##
63.74 ± 9.86 ##

0.99 ± 0.04
1.98 ± 0.13
##
1.99 ± 0.12
##
1.88 ± 0.08
##
1.82 ± 0.05
##
2.01 ± 0.17
##
1.90 ± 0.17
##
1.95 ± 0.17
##

95.97 ± 0.29

0.94 ± 0.03

26.74 ± 2.42

0.99 ± 0.04

96.01 ± 0.55

0.95 ± 0.05

22.10 ± 1.94

0.91 ± 0.02

94.28 ± 0.52

0.85 ± 0.03

22.66 ± 1.98

0.94 ± 0.01

Table 1. Summary of TLR4 and TLR2 expression on DCs. MFIs are expressed as fold
difference in order to combine data obtained from independent experiments. Data
represented as means ± SEM, n=4-7 animals/group from two independent experiments. *,
p<0.05 as compared to unstimulated, ethanol 50 mM and 100 mM groups; #, p<0.05 as
compared to ethanol 250 group; **, p< 0.05 as compared to unstimulated and ethanol
only groups; ##, p<0.0001 as compared to unstimulated and ethanol only groups by
ANOVA with Tukey post-hoc test.
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Figure 4. TLR4 expression on DCs. BM-DCs (2 x 106 cell/well) were cultured in 96-well
plates in the presence of LPS (1 µg/ml) and varying concentrations of ethanol for 24
hours at 37°C. Cells were harvested and cell suspensions were stained with PEconjugated anti-CD11c, FITC-conjugated anti-MHC II and PE-Cy7 conjugated antiTLR4. Representative FACS plots were taken from a single animal (ethanol dose – 50
mM), and demonstrate the percentage of TLR4+ cells (A) and MFI of the TLR4 antibody
conjugate (B) within the DC (MHC II+CD11c+) gate. Numbers indicate the percentage of
cells in each quadrant. Solid black line, unstimulated cells; gray histogram, LPS only
control; dashed line, respective treatment.

the percentage and per cell expression of TLR4 (Fig. 4), suggesting that ethanol does not
influence levels of TLR4 following LPS stimulation. Together these data suggest that the
cytokine changes found following ethanol exposure are independent of TLR4 expression
and may suggest aberrant downstream signaling.
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LPS has been reported to induce expression of TLR2 via activation of TLR4dependent pathways [104, 183, 184]. To assess whether ethanol exposure affects LPS
induction of TLR2 expression, we determined the effects of ethanol on BM-DC
expression of TLR2 by flow cytometry (Fig. 5). Though LPS stimulation alone
significantly increased the percentage of DCs expressing TLR2 by 2.3 fold as compared
with unstimulated cells (Fig. 5A, p<0.05), ethanol treated BM-DCs also demonstrated
similar increases in percent of TLR2+ DCs. Similarly, LPS challenge heightened the MFI
of TLR2, as compared with unstimulated cells (Table 1, p<0.0001). Neither paradigm of
ethanol exposure altered the MFI of TLR2, as compared with BM-DCs cultured with LPS
alone. These results are summarized in Table 1 and indicate that ethanol exposure does
not perturb LPS-induced TLR2 expression.
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Figure 5. TLR2 expression on DCs. BM-DCs (2 x 106 cell/well) were cultured in 96well plates in the presence of LPS (1 µg/ml) and varying concentrations of ethanol for 22
hours at 37°C. Cells were harvested and cell suspensions were stained with PEconjugated anti-CD11c, FITC-conjugated anti-MHC II and Alexa-647 conjugated antiTLR2. Representative FACS plots were taken from a single animal (ethanol dose – 50
mM), and demonstrate the percentage of TLR2+ cells (A) and MFI of the TLR2 antibody
conjugate (B) within the DC (MHC II+CD11c+) gate. Numbers indicate the percentage of
cells in each quadrant. Solid black line, unstimulated cells; gray histogram, LPS only
control; dashed line, respective treatment.

Discussion
The results presented in this article clearly demonstrate that exposure to ethanol
suppresses BM-DC secretion of pro- and anti-inflammatory cytokines that contribute to T
cell polarization, in a manner independent of TLR4 and TLR2 expression. These effects
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are dose-dependent, and are further influenced by the timing of alcohol administration
relative to the LPS challenge. Despite the differential cytokine profiles depending on the
treatment paradigm used, neither ethanol pre-treatment nor concurrent culture with
ethanol and LPS altered TLR4 and TLR2 expression. Our results provide strong evidence
to suggest that ethanol exposure suppresses BM-DC immune responses in a dosedependent manner. While we recognize that our studies were carried out in vitro and may
have limited physiological implications, our results provide strong evidence to suggest
that ethanol exposure suppresses BM-DC immune response in a dose-dependent manner.
The activation of cytokine production and secretion in response to LPS, the main
component of the outer membrane of Gram-negative bacteria, predominantly depends on
TLR4 signaling. When combined with LPS-binding protein, LPS is transferred to TLR4
by CD14, making CD14 a critical adaptor molecule for TLR signaling. Additionally, LPS
ligation to TLR4 requires accessory protein MD-2 to activate TLR4 signaling and induce
transcription of immune response genes [174, 185, 186].
As LPS predominately affects changes in cytokine production via the TLR4
pathway, and indirectly via TLR2, we hypothesized that the cytokine dysregulation
observed in our study may by correlated with altered expression of these pattern
recognition receptors. Previously, several groups have demonstrated that in vivo and in
vitro acute ethanol exposure disrupts macrophage TLR4/CD14 clustering by interfering
with lipid rafts and actin cytoskeleton reorganization following LPS stimulation [187189]. Our study directly examined the effect of ethanol on TLR expression. Though no
alteration in TLR expression was observed in our study, it is possible that these
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mechanisms play a role in the cytokine changes found in DCs following ethanol exposure
and LPS challenge. Additional experiments will explore TLR4/CD14 clustering and
cytoskeleton reorganization in response to LPS to answer whether ethanol exerts its
immunosuppressive effects on DCs by inhibiting proper receptor interactions and/or
subsequent downstream signaling. Moreover, our study found that LPS-induced
expression of TLR2 was not affected by the presence of ethanol; yet, we did not directly
test the functionality of TLR2. Future experimentation with TLR2 specific agonists will
elucidate whether ethanol abrogates TLR2 dependent immune responses.
In our study, we also sought to determine how the timing of ethanol exposure
relative to LPS stimulation affects cytokine secretion. For the Th1 polarizing cytokine IL12, ethanol exposure (50 mM) prior to LPS stimulation generated significantly higher IL12 levels compared with LPS alone and those cells treated concurrently. This is an
interesting observation, suggesting that how ethanol interacts with cellular machinery to
regulate cytokine production may be time dependent. Of note, Mandrekar et al. and Lau
et al. demonstrated that ethanol exposure perturbs differentiation of DCs and subsequent
IL-12 production [164, 165]. In contrast to our study, these studies used ethanol during
the differentiation process, potentially altering additional cell subsets that may impact the
ability of DC precursors to effectively differentiate into functional DCs. Moreover, in
vivo exposure to a single dose of ethanol (2.9 g/kg) results in decreased LPS-induced IL12 production from splenic macrophages, 6 hrs after ethanol injection [158]. Taken
together, these results suggest that the stage of immune cell differentiation and timing of
ethanol exposure may be important factors in driving ethanol induced perturbation of IL-
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12p40 secretion. Further, these data suggest that ethanol exposure may skew the ability of
DCs to aid in T cell polarization following immune challenge.
In reference to IL-6 and IL-23, DC secreted cytokines that work in concert to
drive naïve T cells toward the Th17 phenotype, pre-treatment with ethanol exerted a more
robust cytokine suppression after LPS stimulation as compared with co-cultured cells. As
mentioned previously, IL-23 is a member of the IL-12 family, and both cytokines share
the p40 subunit. The role of the p40 subunit has long been described as crucial for the
biological functions of IL-12, as the IL-12R recognizes the heterodimeric structure.
However, until the discovery of the IL-23 p19 subunit, it was thought that excess p40
formed homodimers, which exert antagonistic effects to IL-12 [190]. It is now understood
that the p40 subunit may combine with p35 to form IL-12p70, p19 to form IL-23 or form
homodimers [34, 190, 191]. Today, IL-23 is recognized for its role in promoting the
production of Th17 effector cytokines IL-17 and IL-22 [28, 31, 33]. Interestingly, in BMDCs treated with ethanol prior to LPS culture, there was a dramatic decrease in IL-23
with a relative increase in IL-12. On the other hand, concomitant treatment with ethanol
and LPS resulted in a reduction of both cytokines. These data may suggest that ethanol
exposure in advance of an immune challenge may preferentially shift the utility of the
p40 subunit towards IL-12 production. Although not examined in this study, others have
shown that LPS/TLR4 mediated induction of IL-23 p19 expression depends on NF-κβ
and AP-1 [172], which are modulated by MyD88 and MAPK pathways, respectively. In
regards to AP-1, Liu et al. were the first to establish that AP-1acts to promote expression
of IL-23 p19 under the direction of ERK [172]. Of note, ERK is also a known regulator
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of the p40 subunit of IL-23, the subunit which is shared with IL-12; however, while ERK
promotes expression of p19, it inhibits expression of p40 [192], suggesting that ethanol
may impact ERK activity and relative expression of these subunits.
Alterations in ERK activity, in conjugation with other members of either the
MAPK or MyD88 pathway have be attributed to alterations in IL-6 following acute
ethanol treatment. In vivo acute ethanol exposure reduces LPS-induced IL-6 production
from splenic macrophages [113, 114, 158]. Goral et al. further demonstrated that ethanol
modulates IL-6 by transiently down-regulating the activation of p38 and ERK in
unstimulated and LPS challenged splenic macrophages [113, 114]. Our results indicate
that when pre-treated with ethanol, LPS-induced DC IL-6 production is suppressed in a
dose dependent manner, suggesting that ethanol modulates IL-6 release in fully
differentiated DCs. While further experimentation to determine the effect of ethanol on
p38 and ERK pathways in BM-DCs in response to LPS, these previous studies support
the idea that ethanol decreases ERK activity. As mentioned above this ethanol-mediated
reduction in ERK activity could explain the diminished secretion of the Th17 polarizing
cytokines IL-6 and IL-23, and the elevation of Th1 skewing IL-12p40 in a timedependent manner. The temporal role of ERK in DC cytokine production as well as other
functional measures of DC activity will be the focus of future studies.
While our pro-inflammatory cytokine data supports previous findings regarding
ethanol and immune cell subsets, it is clear that more research needs to be conducted to
examine the impact of ethanol on DC immune function. Moreover, even less is
understood about the effects of ethanol on DC anti-inflammatory profiles. Current
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literature focusing on DCs IL-10 production is limited to studies of human peripheral
blood monocyte derived DCs. In their study, Mandrekar et al. report an increase in LPSinduced IL-10 from DCs generated in the presence of ethanol [164]. While the range of
IL-10 levels we obtained correlate with these data, we demonstrate a dose dependent
suppression of LPS-induced IL-10, which is further exacerbated if DCs are pre-treated
with ethanol prior to LPS stimulation. Moreover, Mandrekar et al. demonstrated
increased IL-10 from DCs generated in the presence of ethanol, irrespective of LPS
stimulation. In our studies, we found that ethanol alone does not induce a detectable level
of IL-10. These disparities in our data may be due to differences in cell population and
differentiation methods as discussed previously. Together, these data imply that ethanol
has a differential role in anti-inflammatory cytokine production that may be due to the
impact of ethanol on DC differentiation and maturation.
In conclusion, our study demonstrates that acute ethanol exposure dysregulates
LPS-induced immune responses irrespective of affecting TLR4 or TLR2 expression.
These effects also appear to be related to the timing of ethanol exposure relative to
immune challenge, as our data suggests that ethanol exposure prior to LPS impairs IL-23
and IL-6 secretion, and shunts the immune response towards an IL-12 response. While
further studies need to be conducted to elucidate the immunomodulatory mechanisms
altered by ethanol in DCs, the ethanol induced cytokine dysregulation observed in this
study is an important consideration when investigating the role of ethanol in DC/Th17
cell mediated pathologies such as rheumatoid arthritis and inflammatory bowel disease.

CHAPTER 4
THE ROLE OF ARYL HYDROCARBON RECEPTOR IN IL-23 DEPENDENT
RELEASE OF IL-22 FOLLOWING ETHANOL EXPOSURE AND BURN INJURY
Abstract
T helper (Th)-17 lymphocytes play a crucial role in the maintenance and
regulation of gut immunity. Our laboratory has demonstrated that acute ethanol (EtOH)
exposure prior to burn injury results in intestinal T cell suppression and enhanced
bacterial translocation. We examined the effects of EtOH exposure and burn injury on
Th17 responses within intestinal lymphoid Peyer’s patches (PP). We further investigated
whether restitution of IL-23 modulates PP cell IL-17 and IL-22 following EtOH and burn
injury. Male mice, ~25g, were gavaged with EtOH (2.9mg/kg) prior to receiving a
~12.5% total body surface area full thickness burn. One day post injury, PP mixed cells
were cultured in the presence of plate bound anti-CD3/soluble anti-CD28 in presence or
absence of rIL-23 for 48 h. Supernatants were harvested for IL-17 and IL-22 levels.
When combined with EtOH intoxication, burn injury significantly decreased IL-17 and
IL-22, as compared to sham injury. Restitution of IL-23 successfully restored IL-22, but
not IL-17 following EtOH intoxication and burn injury. However, IL-23 restoration of
IL-22 was prevented in PP cells treated with CH-223191, an inhibitor the aryl
hydrocarbon receptor (AhR). To further delineate the mechanism of suppressed IL-17
and IL-22, PP cells were treated with phorbol 12-myristate 13-acetate (PMA) and
ionomycin. We found that, PMA and ionomycin significantly prevented the decrease in
53
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IL-17 but not IL-22. Collectively, these findings suggest that IL-23 mediated restoration
of IL-22 is dependent on the AhR following EtOH and burn injury. Conversely, IL-17
requires activation of PKC and intracellular calcium signaling.
Introduction
More than one million burn injuries are reported yearly within the United States
[1]. These injuries translate into an approximate 500,000 emergency room visits and
40,000 hospitalizations annually [1]. Interestingly, nearly one-half of these injuries occur
under the influence of alcohol/ethanol (EtOH) intoxication [2-4, 6, 8, 11]. Furthermore,
burn victims who sustain injury post EtOH exposure are more susceptible to infection,
exhibit higher morbidity, and are more likely to die than patients without EtOH exposure
at the time of injury [2-4, 6, 11-13]. Previous data suggest that gut pathogens and their
products may play a pivotal role in the development of sepsis and multiple organ failure
reported in burn and trauma patients [14, 59, 128, 193]. In line with these studies, our
laboratory has demonstrated increased intestinal tissue damage, leakiness, and bacterial
translocation as well as T lymphocyte, particularly T helper (Th) cell, suppression
following EtOH intoxication and burn injury [14-21, 112]. We observed that ethanol
combined with burn injury results in decreased Th1 cytokine IFN-γ production [16, 17,
112].
Recent findings suggest that Th17 lymphocytes maintain intestinal immune
homeostasis and barrier function [22-25, 39, 85, 86]. Furthermore, IL-23, a heterodimeric
cytokine and member of the IL-12 family, has been shown to play a critical role in the
development, expansion and survival of Th17 lymphocytes [31-33]. Binding of IL-23 to
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its receptor complex on differentiating T helper lymphocytes activates signal transducer
and activator of transcription (STAT)-3 to maintain upregulation of transcription factor
retinoic acid related orphan receptor (ROR)-γt, which is indispensable in the production
and secretion of Th17 effector cytokines IL-17 and IL-22 [67, 88-91]. IL-17 has been
shown to protect against gut pathogens, including Bacteriodes fragilis and Klebsiella
pneumoniae [22-25], as well as to enhance tight junction formation [80]. Conversely, IL22 acts on epithelial cells to induce release of antimicrobial peptides (AMPs) [29, 30] and
stimulate epithelial cell regeneration and proliferation [23, 47]. Furthermore,
dysregulation of Th17 lymphocytes has been implicated in both forms of inflammatory
bowel disease [76-78].
More recently, suppression of Th17 generation was reported in patients with
severe burn injuries [139]. Our study examined whether Th17 effector cytokines IL-17
and IL-22 are affected by combined EtOH and burn injury in gut associated secondary
lymphoid organs, Peyer’s patches (PPs). PPs are important intestinal secondary lymphoid
organs that play a critical role in T cell immunity, as well as gut bacterial translocation
and its containment [85, 194]. Our results demonstrate that EtOH and burn injury results
in suppressed CD3-dependent Th17 cytokines IL-17 and IL-22. Moreover, restitution
with IL-23 successfully restores IL-22, but not IL-17, suggesting a differential role for
IL-23 following EtOH intoxication and burn injury. Lastly, we treated PP cells with an
inhibitor the aryl hydrocarbon receptor (AhR) as well as phorbol 12-myristate 13acetate
(PMA) and ionomycin to determine the molecular mechanism by which EtOH and burn
injury modulates Th17 cytokines IL-17 and IL-22. We found that following EtOH and
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burn injury, IL-23 dependent restoration of IL-22 is regulated, at least in part, by the
AhR. On the other hand, IL-17 is induced by PMA and ionomycin, suggesting a role for
intracellular calcium signaling in perturbation of IL-17 following EtOH and burn injury.
Material and Methods
Animals and reagents
Male C57BL/6 mice, 6-7 wk old, were obtained from Harlan Laboratories.
Hamster anti-mouse CD3e and anti-mouse CD28 were obtained from BD Biosciences
(San Diego, CA). Rat affinity purified anti-mouse CD16/32, hamster PE-conjugated antimouse CD11c, rat FITC-conjugated anti-mouse MHC II, rat APC-conjugated anti-mouse
F4/80, hamster PE-Cy7-conjugated anti-mouse CD3e and recombinant IL-12 and IL-23
were obtained from eBioscience (San Diego, CA). Goat APC-conjugated anti-mouse IL23R and IL-17 and IL-22 ELISA kits were obtained from R&D Systems (Minneapolis,
MN). Collagenase D was obtained from Roche Applied Science (Indianapolis, IN).
Concanavalin A, ionomycin calcium salt, phorbol 12-myristate 13-acetate (PMA), and
AhR inhibitor CH-223191 were obtained from Sigma-Aldrich (St. Louis, MO).
Mouse model of acute EtOH intoxication and burn injury
As previously described [195], adult C57BL/6 male mice were randomly divided
to receive sham or burn injury and either ethanol (EtOH) or vehicle (water) to yield four
experimental groups: sham vehicle (SV), sham EtOH (SE), burn vehicle (BV) and burn
EtOH (BE). Mice were gavaged with either 0.4 ml of 25% EtOH in water (~2.9 g/kg) or
water. Four hours after gavage, mice were anesthetized by i.p. injection of ketamine
hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg, respectively). Dorsal
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surfaces were shaved, and animals were transferred into a template fabricated to expose
~12.5% of the total body surface area (TBSA). TBSA was calculated by using Meeh’s
formula as described by Walker and Mason [196]. Burn-injured mice were immersed into
a water bath maintained at 85-87C for 7 s, which results in a 3rd degree full thickness
scald injury. Sham-injured mice were subjected to identical anesthesia and treatment, but
immersed into isothermic water (37°C) for 7 s. Immediately after burn or sham
procedure, animals were dried and resuscitated with 1.0 ml physiological saline by i.p
injection. Animals were allowed food and water ad libitum. All experiments were
conducted in accordance with the guidelines set forth in the Animal Welfare Act and
were approved by the Institutional Animal Care and Use Committee at the Loyola
University Health Sciences Division.
Cell isolation from PPs
One day after injury, mice were anesthetized and the abdominal cavity exposed
via midline incision. PPs were collected aseptically and placed into a Collagenase D
bathe for 15min at 37°C, as described previously [197]. Collagenase D (0.5 mg/ml) was
prepared in Hank’s Buffered Saline Solution (HBSS, Fisher Scientific) containing Ca2+
and Mg2+ and supplement with 10 mM HEPES, 50 µg/ml gentamicin, 100 U/ml
penicillin with 100 µg/ml streptomycin and 5% FCS. Following Collagenase D treatment,
PPs were crushed to prepare single-cell suspensions, filtered through a 70 µm Nylon
filter, washed and resuspended at a concentration of 5x106 cells/ml in complete media
(RPMI 1640 supplemented with 2 mM L-glutamine, 10 mM HEPES, 50 µg/ml
gentamicin, 100 U/ml penicillin with 100 µg/ml streptomycin and 10% FCS).
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Flow cytometry analysis
For the measurement of PP T cell, macrophage and dendritic cell populations, PP
mixed cells were resuspended in FACS buffer (PBS with 5% FCS) at a concentration of 2
x 106 cells/ml. Cells suspensions were blocked with purified anti-mouse CD16/32 for 20
min at 4°C and stained with PE-Cy7 conjugated anti-mouse CD3e, PE conjugated antimouse CD11c, APC conjugated anti-F480 and FITC conjugated anti-mouse MHC II for
30 min in the dark at 4°C. For the measurement of IL-23 receptor expression, PP mixed
cells (2 x 106 cells/mL) were cultured in 96-well plates in the presence of plate bound
anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) for 4 h. Cells were collected,
blocked with purified anti-mouse CD16/32 for 20 min at 4°C and stained with PE-Cy7
conjugated anti-CD3e and PE conjugated anti-IL-23R for 30 min in the dark at 4°C. The
cells were washed twice and resuspended in 0.5 ml FACS buffer. All samples were
analyzed at the Loyola University Health Sciences Division FACS Core Facility using a
six-color flow cytometer (BD FACSCanto) and FlowJo Software (Treestar). CD3e+ cells
were identified as T cells, CD11c+MHC II+ cells were considered dendritic cells and
F480+ cells were considered macrophages.
Measurement of IFN-γ, IL-2, IL-17 and IL-22
Experiment 1: To determine the effects of EtOH exposure and burn injury on T
helper effector cytokines IFN-, IL-2, IL-17 and IL-22, mixed cells (2 x 106 cells/ml)
were cultured in the presence of ConA (5 g/ml) or T cell specific stimuli, plate bound
anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml), in 96-well plates at 37°C and 5%
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CO2 for 48 h [33]. Following culture, supernatants were harvested and tested for IFN-γ,
IL-17 and IL-22 levels, using respective ELISA kits.
Experiment 2: To assess whether rIL-23 restores IL-17 and IL-22 following
combined injury, mixed cells (2 x 106 cells/ml) were cultured in the presence of plate
bound anti-CD3 (5 µg/ml) + soluble anti-CD28 (1 µg/ml) +/- rIL-23 (10 ng/ml) +/- rIL12 (10 ng/ml) in 96-well plates at 37°C and 5% CO2 for 48 h [31, 33, 89]. Supernatants
were harvested and IFN-, IL-17 and IL-22 measured by ELISA.
Experiment 3: To investigate the role of the AhR transcription factor in IL-23
dependent restoration of IL-22, mixed cells (2 x 106 cells/ml) were pre-treated with AhR
inhibitor CH-223191 (10 µM) for 2 h, as previously described [198], prior to being
cultured in the presence plate bound anti-CD3 (5 µg/ml) + soluble anti-CD28 (1 µg/ml)
+/- rIL-23 (10 ng/ml) in 96-well plates at 37°C and 5% CO2 for 48 h. IL-17 and IL-22
were measured in culture supernatants.
Experiment 4: To explore the role of intracellular calcium signaling on Th17
effector cytokines IL-17 and IL-22 following EtOH and burn injury, mixed cells cells (2
x 106 cells/ml) were cultured in the presence plate bound anti-CD3 (5 µg/ml) + soluble
anti-CD28 (1 µg/ml) +/- PMA (10 ng/ml) and ionomycin (50 ng/ml)in 96-well plates at
37°C and 5% CO2 for 48 h. IL-17 and IL-22 were measured in culture supernatants.
Statistical analysis
The data, wherever applicable, are presented as means + SEM and were analyzed
using ANOVA with Tukey’s post hoc test or Student’s test (GraphPad InStat). p<0.05
was considered statistically significant.
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Results
PP immune cells following ethanol and burn injury
We determined the effect of EtOH and burn injury on PP T cells (CD3e+),
dendritic cells (CD11c+MHC II+) and macrophages (F480+) by flow cytometry. As
summarized in Table 2, the percentage of PP immune cells remained unaffected
following EtOH and/or burn injury.

T cells (%)

Dendritic Cells (%)

Macrophages (%)

(CD3e+)

(CD11c+MHC II+)

(F4/80+MHC II+)

Sham Vehicle

19.57 ± 1.74

3.23 ± 0.21

0.26 ± 0.04

Sham EtOH

18.97 ± 1.84

3.03 ± 0.20

0.26 ± 0.06

Burn Vehicle

24.46 ± 2.25

3.09 ± 0.20

0.24 ± 0.02

Burn EtOH

22.58 ± 1.82

3.21 ± 0.18

0.25 ± 0.02

Table 2. Percentage of T cells, dendritic cells and macrophages in PPs after EtOH
intoxication and burn injury. PPs were harvested one day post injury, processed for
single cell suspension and resuspended in FACS buffer at a concentration of 2 x 106
cells/ml. Cells suspensions were blocked with purified anti-mouse CD16/32 for 20 min at
4°C and stained with PE-Cy7 conjugated anti-mouse CD3e, PE conjugated anti-mouse
CD11c, APC conjugated anti-F480 and FITC conjugated anti-mouse MHC II for 30 min
in the dark at 4°C. The cells were washed twice, resuspended in 0.5 ml FACS buffer and
analyzed by flow cytometry. CD3e+ cells were identified as T cells, CD11c+MHC II+
cells were considered dendritic cells and F480+MHC II+ cells were considered
macrophages. Data represent frequency of T cells, dendritic cells and macrophages per
live events. Data are represented as mean ± SEM, n=8-12 animals/group from two
independent experiments.
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EtOH and burn injury suppresses PP Th17 effector cytokines IL-17 and IL-22
Our laboratory has previously demonstrated that EtOH intoxication and burn
injury suppresses gut associated T cell IFN-γ and IL-2 in a rat model [17, 18, 112]. To
further elucidate the effects of EtOH intoxication and burn injury on T helper responses,
we examined whether combined insult affects Th17 effector responses in PPs. To test
this, PP mixed cells were cultured with ConA (5 µg/ml, see Appendix 2A) or T cell
specific stimuli, plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml), for 48
h. Following culture, cell supernatants were harvested, and IL-17 (Fig. 6A) and IL-22
(Fig. 6B) were measured. As demonstrated in Fig. 6, we found no significant change in
PP IL-17 and IL-22 in mice gavaged with EtOH alone. Following burn injury, IL-17 and
IL-22 were both decreased as compare to sham vehicle. Of note, burn induced
suppression of IL-17 and IL-22 was significantly exacerbated in the presence of EtOH
intoxication. In our preliminary studies we used ConA as a T cell stimulant and found
similar results to T cell specific CD3/CD28. However, to explicitly study the effects of
EtOH and burn injury on CD3/CD28 mediated Th17 effector responses, further
experiments utilized anti-CD3 and anti-CD28 as T cell stimuli. Moreover, the greatest
suppression of Th17 effector cytokines was found in animals subjected to combined
EtOH exposure and burn injury; thus, the remaining studies were carried out using only
the sham vehicle and burn EtOH groups.
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Figure 6. EtOH and burn injury suppresses PP Th17 effector cytokines IL-17 and IL-22.
PP mixed cells (2 x 106 cells/ml) were cultured in 96-well plates in the presence of plate
bound anti-CD3 (5µg/mL) and soluble anti-CD28 (1µg/mL) for 48 h at 37°C.
Supernatants were harvested for the measurement of IL-17 (Panel A) and IL-22 (Panel B)
(IL-17 and IL-22 ELISA Kits, R&D Systems). Values are means + SEM, n=5-11
animals/group, from three independent experiments. *, p<0.001 as compared with sham
vehicle; †, p<0.01 and ‡, p< 0.001 as compared with sham EtOH by ANOVA with
Tukey’s post hoc test. §, p<0.05 as compared with burn vehicle by student’s t-test.
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To test whether the decreased Th1 effector cytokines, IFN-γ and IL-2, exist in
mouse PPs, mixed cells were cultured with ConA for 48 h. Following culture, cell
supernatants were harvested for the measurement of IFN-γ and IL-2. As shown in Fig. 7,
combined insult suppressed Th1 effector cytokines IFN-γ (Fig. 7A) and IL-2 (Fig. 7B), as
compared with sham injury.
PP IL-23 and IL-23 receptor expression
IL-23 is synthesized by a variety of cells, including monocytes, macrophages,
dendritic cells, T cells, B cells and endothelial cells [34, 97]. Given its central role
mediating Th17 effector responses, we tested whether EtOH and burn injury perturbs IL23. Mixed cells were cultured in the presence of LPS (1 µg/ml) for 24 h. Following
culture, cell supernatants were collected for protein measurement and cells lysed for
intracellular IL-23 protein levels. In our initial studies we measured the p40 subunit of
IL-23, which is also shared by IL-12. As demonstrated in Fig. 8A, EtOH and burn injury
suppressed IL-12/23p40 in cell culture supernatants, as compared with sham injury. We
next measured IL-23p19, the subunit unique to IL-23, in cell culture supernatants and
found that the levels of IL-23p19 were below the level of detection (data not shown). To
circumvent this, we measured IL-23p19 in cell lysates. Our results, Fig. 8B, show that IL23p19 is detectable only in sham vehicle samples, suggesting that combined EtOH and
burn injury suppresses IL-23p19.
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Figure 7. PP IFN-γ and IL-2 are decreased following EtOH and burn injury. PP mixed
cells (2 x 106 cells/ml) were cultured in 96-well plates in the presence of ConA (5µg/ml)
for 48 h at 37°C. Supernatants were harvested for the measurement of IFN-γ (Panel A)
and IL-2 (Panel B) (IFN-γ and IL-2 ELISA Kits, BD Bioscience). Values are means +
SEM, n=4-6 animals/group. *, p<0.05 and †, p<0.005 as compared with sham vehicle
group by student’s t-test.
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Figure 8. PP IL-23. PP mixed cells (2 x 106 cells/ml) were cultured in 96-well plates in
the presence of LPS (1 µg/ml) for 24 h. Supernatants were harvested for the measurement
of IL-12/23p40 (panel A) (IL-12p40 ELISA Kit, BD Bioscience). Cell culture
supernatants were collected for IL-23p19 protein measurement and cells lysed for
intracellular IL-23p19 protein levels (Panel B) by ELISA (IL-12/23p40 ELISA kit, BD
Sciences; IL-23p19 ELISA kit, R&D Systems). Values are means + SEM, n=3-8
animals/group. *, p<0.05 as compared with sham vehicle by student t-test.
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We further determined whether EtOH exposure and burn injury perturb
expression of the IL-23 receptor (IL-23R). To accomplish this, PP cells were stimulated
with plate bound anti-CD3 (5 μg/ml) and soluble anti-CD28 (1 μg/ml) for 4 h. After
incubation, cells were harvested and stained with PE-Cy7 conjugated anti-mouse CD3e
and PE conjugated anti-mouse IL-23R, CD3e and IL-23R co-expression was determined
by flow cytometry (Fig. 9). We found that only 2-3% of PP cells co-express CD3e and
IL-23R following 4 h of culture. However, EtOH intoxication and burn injury did not
significantly affect the frequency (percent) of CD3e+IL-23R+ event (data not shown), nor
the per cell expression of IL-23R within CD3e+ cells.
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Figure 9. EtOH exposure and burn injury does not influence IL-23 receptor expression.
PP mixed cells (2 x 106 cells/mL) were cultured in 96-well plates in the presence of plate
bound anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) for 4 h. Cells were collected
and stained with PE-Cy7 conjugated anti-CD3e and PE conjugated anti-IL-23R.
Expression of CD3e and IL-23R were determined by flow cytometery. Panel A,
representative FACS plots demonstrate the MFI of IL-23R antibody conjugate: gray
histogram, fluorescence minus one control; solid black line, respective treatment. Panel
B, cumulative IL-23R MFI expression data, values are means + SEM from 4
animals/group.
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IL-23 specifically restores IL-22, but not IL-17, following combined injury
Differentiation of Th17 lymphocytes depends on IL-1β, IL-6 and TGF-β;
however, IL-23 is crucial to Th17 effector function. IL-23 shares the p40 subunit of IL12, where p40 joins with the p19 subunit to form IL-23, p40 can also join with the p35
subunit to form IL-12 [34]. We tested whether IL-23 restitution prevents decreased IL-17
and IL-22 following EtOH and burn injury. Since IL-23 shares one subunit with IL-12
and we have previously shown decreased IL-12 following EtOH and burn injury [17], we
confirmed whether IL-12 influences IL-17 and IL-22. PP mixed cells were cultured with
plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml) in the presence or
absence of rIL-12 (10 ng/ml) or rIL-23 (10 ng/ml) for 48 h. Following culture, cell
supernatants were harvested, and IFN-γ (Fig. 10A), IL-17 (Fig. 10B) and IL-22 (Fig.
10C) were measured by ELISA. Similar to our previous findings [17], the results
presented in Fig. 10A confirm that IL-12 restores IFN-γ following EtOH intoxication and
burn injury in PP cells. This effect is specific to IL-12 as treatment with IL-23 does
significantly affect IFN-γ. In regards to Th17 effector cytokines, our results demonstrate
a differential role of IL-23 in modulation of IL-17 and IL-22. The results in Fig. 10B
demonstrate that neither IL-12 nor IL-23 treatment modulates PP IL-17. Conversely, IL23 treatment significantly increased IL-22 in both sham and burn EtOH samples,
suggesting the IL-23 restores IL-22 following ethanol intoxication and burn injury.
Moreover, IL-12 did not affect IL-22 in either sham or burn EtOH, confirming that
restoration of IL-22 is truly IL-23 dependent. Together these results suggest that IL-23
restores IL-22, but not IL-17 following ethanol and burn injury.
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Figure 10. IL-23 specifically restores PP IL-22, but not IL-17, following EtOH
intoxication and burn injury. PP mixed cells (2 x 106 cells/mL) were cultured in 96-well
plates in the presence of plate bound anti-CD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml)
in the presence or absence of rIL-23 (10 ng/ml) or rIL-12 (10 ng/ml) for 48 h.
Supernatants were harvested for the measurement of IFN-γ (Panel A), IL-17 (Panel B)
and IL-22 (Panel C) (IFN-γ ELISA Kit, BD Bioscience; IL-17 and IL-22 ELISA Kit,
R&D Systems). Values are means + SEM, n=6-14 animals/group, representative of two
independent experiments. *, p<0.001 as compared with all groups; †, p<0.05 as compared
with respective sham vehicle; ‡, p<0.001 as compared with respective anti-CD3/28 and
anti-CD3/28 + rIL-12 groups by ANOVA with Tukey’s post hoc test. §, p<0.05 as
compared with respective sham vehicle by Student’s t-test.
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AhR modulates IL-23 dependent restoration of IL-22 following EtOH and burn
injury
Our results indicating divergent roles of IL-17 and IL-22, in response to IL-23,
led us to examine the role of the AhR, a ubiquitous transcription factor found in the
cytoplasm of vertebrate cells, in IL-23 dependent restoration of IL-22. While the AhR has
been recently implicated in the regulation of IL-22 [44, 45, 106, 107], and less so IL-17,
the mechanisms by which IL-23 and the AhR modulate IL-22 remain poorly described.
We examined whether IL-23 dependent restoration of IL-22 is modulated by AhR. Mixed
PP cells were pre-treated with AhR inhibitor CH-223191 (10 µM) for 2 h, prior to being
cultured with plate bound anti-CD3 (5 µg/ml) and soluble anti-CD28 (1 µg/ml) in the
presence or absence of rIL-12 or rIL-23. Following 48 h of culture, cell supernatants were
collected and tested for IL-17 (Fig. 11A) and IL-22 (Fig. 11B). Our data demonstrate that
PP cells treated with an inhibitor to the AhR, prior to restitution of IL-23, produced
significantly less IL-22. However, inhibition of the AhR did not affect IL-17. Together
these results suggest that IL-23 dependent restoration of IL-22 is modulated, at least in
part, by the AhR and further support divergent roles of IL-23 in Th17 effector functions
following ethanol intoxication and burn injury.
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Figure 11. AhR modulates IL-23 dependent restoration of IL-22 following combined
injury. PP mixed cells (2 x 106 cells/mL) were treated with AhR inhibitor CH-223191 (10
µM) for 2 h prior to being cultured in 96-well plates in the presence of plate bound antiCD3 (5µg/ml) and soluble anti-CD28 (1 µg/ml) in the presence or absence of rIL-23 (10
ng/ml) for 48 h. Supernatants were harvested for the measurement of IL-17 (Panel A) and
IL-22 (Panel B) (IL-17 and IL-22 ELISA Kit, R&D Systems). Values are means + SEM,
n=9-17 animals/group, representative of three independent experiments. *, p<0.01 as
compared with respective sham vehicle; ‡, p<0.01 as compared with respective antiCD3/28 and anti-CD3/28 + CH-223191 groups by ANOVA with Tukey’s post hoc test.
†, p<0.05 as compared with respective sham vehicle by Student’s t-test.
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IL-17 requires intracellular calcium signaling following EtOH and burn injury
To further decipher the differential effects of EtOH exposure and burn injury on
IL-17 and IL-22 following, PP cells were treated with PMA and ionomycin, which
directly activates Protein kinase C (PKC) and intracellular Ca2+ signaling. Mixed PP cells
were cultured with plate bound anti-CD3 (5 µg/ml), soluble anti-CD28 (1 µg/ml), PMA
(10 ng/ml) and ionomycin (50 ng/ml) for 48 h. Following cell culture, cell supernatants
were collected and tested for IL-17 (Fig. 12A) and IL-22 (Fig. 12B). We found that
treatment of cells with PMA and ionomycin restores PP IL-17 levels to that of sham
vehicle levels. However, PMA and ionomycin treatment does not affect IL-22. Together,
these data highlight the importance of PKC and intracellular Ca2+ in the induction of IL17, but not IL-22, which supports recent data indicating differential regulation of IL-17
and IL-22.
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Figure 12. IL-17 requires intracellular calcium signaling following EtOH and burn
injury. PP mixed cells (2 x 106 cells/mL) were cultured in 96-well plates in the presence
of plate bound anti-CD3 (5µg/ml), soluble anti-CD28 (1 µg/ml), PMA (10 ng/ml) and
ionomycin (50 ng/ml) for 48 h. Supernatants were harvested for the measurement of IL17 (Panel A) and IL-22 (Panel B) (IL-17 and IL-22 ELISA Kit, R&D Systems). Values
are means + SEM, n=6-16 animals/group, representative of three independent
experiments. *, p<0.05 as compared with respective sham vehicle (t-test for IL-22); †,
p<0.01 as compared with respective anti-CD3/28 group by ANOVA with Tukey’s post
hoc test.
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Discussion
The data presented in this article clearly demonstrate that acute EtOH exposure
prior to burn injury results in suppressed CD3/28 dependent expression of Th17 effector
cytokines IL-17 and IL-22 in PP cells. While our findings suggest that IL-23 restitution
effectively restores IL-22, it does not modulate IL-17. We further found that IL-23
mediated restoration of IL-22 is dependent on the AhR. IL-17, on the other hand, requires
activation of PKC and intracellular calcium signaling, as demonstrated by increased
levels of IL-17 following treatment with PMA and ionomycin. Altogether, our results
provide novel evidence suggesting that IL-23 differentially regulates Th17 effector
cytokines IL-17 and IL-22 following EtOH and burn injury, and further indicate a crosstalk between IL-23 and the AhR.
T helper cells, including Th17 cells, are of critical importance to mucosal
immunity, barrier function and the containment of pathogenic gut bacteria [22, 23, 23-25,
29, 30, 80]. Gut bacterial pathogens are often implicated in pathogenesis associated with
EtOH and/or burn injury. For these studies we focused on gut associated lymphoid organs
PPs, since they are of central importance to gut bacteria translocation and their
containment [85, 199, 200]. Specifically, PPs are secondary lymphoid organs along the
small intestine, which are lined by specialized epithelial cells, “M” cells. Similar to
antigen presenting cells, including dendritic cells, M cells come in direct contact with
luminal content. Under normal conditions, pathogens that cross the epithelial barrier are
limited from invading the host by the immune cells within PPs, including T helper cells
[85, 86, 200]. Several studies exploring the role of T cells demonstrate that athymic
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(nu/nu) mice, which lack mature T cells, have increased bacterial translocation to
mesenteric lymph nodes (MLN), spleen and liver [201]. Together these findings define an
interdependent relationship between PPs, T cells and containment of gut bacteria. In the
context of EtOH exposure, chronic EtOH feeding has been linked with decreased total, T
and B cells in PPs of animals subjected to chronic EtOH feeding as compared to control
animals [194]. In regards to EtOH and burn, our laboratory has demonstrated decreased T
cell proliferation and Th1 immune functions in T cells from PPs and MLN, as well as
increased bacterial translocation to MLN [14-17, 19-21, 112]. Additionally, our
laboratory found that depletion of CD3+ T cells from normal animals increases bacterial
accumulation in MLN. We further showed that depletion of T cells in animals receiving
EtOH and burn injury results in systemic invasion of bacteria, including spleen and
systemic circulation [18]. The results presented in this article are the first to elucidate the
effects of EtOH and burn injury on Th17 immune responses within PPs. Since Th17 cells
have been implicated in defense against gut pathogens [22-25], a suppression of Th17
effector functions may contribute to the increased bacterial translocation and gut barrier
dysfunction following combined insult of EtOH intoxication and burn injury.
Our initial results indicating suppression of Th17 effector cytokines IL-17 and IL22 following EtOH exposure and burn injury, led us to examine the effects of injury on
PP cell composition. As demonstrated in Table 2, we did not find any change in the
percent (frequency) of T cells, macrophages or dendritic cells. Therefore, it is possible
that the ability of T cells to respond to antigenic stimuli is diminished following EtOH
exposure and burn injury. Moreover the suppression of Th17 cytokines could also result
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from a decrease in IL-23, a cytokine needed for Th17 differentiation. Thus, we focused
on restituting IL-23 and defining the pathways involved in modulation of IL-17 and IL22 post EtOH exposure and burn injury.
We observed a decrease in IL-23 levels in PP following ethanol and burn injury.
Since IL-23 plays a role in Th-17 differentiation [31-33], we investigated whether the
restitution of IL-23 prevents Th17 cytokine suppression following ethanol and burn
injury. Our laboratory recently demonstrated decreased IL-12 following EtOH and burn
injury, as well as successful restoration of Th1 cytokines IFN-γ and IL-2 following
restitution of IL-12 [17]. In this study, we attempted to measure IL-23, as well as IL12/23p40, in PP cell culture supernatants stimulated with LPS. While we found decreased
IL-12/23p40 in cells from EtOH and burn injured mice, we were only able to measure IL23 in cell lysates from the shame vehicle group. Levels of IL-23 were undetectable in cell
lysated from the EtOH and burn group. As shown in Table 2, there was no change in the
percent of macrophages or dendritic cells following EtOH and burn injury; nonetheless, it
possible that their ability to produce IL-23 is impaired following EtOH and burn. IL-12
and IL-23 share a common subunit, the p40 subunit, and have been suggested to have
common roles in driving Th1 and Th17 adaptive immune responses, though this remains
controversial [34, 41, 202]. Therefore, we tested the effects of IL-12 and IL-23 on IFN-γ,
IL-17 and IL-22 in our murine model of EtOH exposure and burn injury. As previously
published [17], our results demonstrate effective restoration of IFN-γ following
restitution of IL-12, with no significant change in IFN-γ following restitution of IL-23.
Though we expected restoration of IL-17 and IL-22 following restitution of IL-23, the
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addition of IL-23 only induced IL-22, not IL-17, with no effects in response to IL-12.
These effects were not due to changes in IL-23 receptor expression on CD3+ T cells. It is
possible that IL-17 requires restitution of other Th17 inducing cytokines, including IL-6
and TGF-β. Differential requirements for effective expression of IL-17 and IL-22 might
explain our divergent results. Recently, Duhen et al. reported low expression of RORC
(ROR-γt in humans) in the IL-22 producing cells, and concluded that RORC is nonessential to expression of IL-22 [44]. It may be that EtOH and burn injury inhibit IL-23
dependent induction of ROR-γt, and thus prevent IL-23 induction of IL-17. Further
studies will examine the effects of EtOH and burn injury on the IL-23 signaling pathway,
including activation of STAT3 and expression of ROR-γt.
While our results partly support previous literature indicating a requirement for
IL-23 in expression of Th17 effector cytokine IL-22 [37, 203], our IL-17 results suggest a
divergent role for IL-23. New data investigating the molecular pathways that control IL17 and IL-22 expression increasingly demonstrate differential regulation of these Th17
effector cytokines [44, 45, 101, 102, 107, 110, 110]. Among the multiple regulators of
IL-17 and IL-22 are various transcription factors, including STAT3, ROR-t and, most
recently, the AhR. While it is generally accepted that IL-6 and IL-23 activate STAT3
[88], to in turn activate expression of Th17 hallmark transcription factor ROR-t, how
AhR regulates IL-22 remains unclear. The AhR is a cytosolic ligand-activated
transcription factor. Upon ligand binding, AhR translocates to the nucleus, where it
dimerizes with AhR nuclear translocator and activates gene transcription [204]. In our
study, we utilized an inhibitor to that binds the AhR and prevents translocation to the
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nucleus [198], to demonstrate that IL-23 dependent induction of IL-22 utilizes the AhR.
While our data indicate cross-talk between IL-23 and the AhR, further studies will be
carried out to test how these two pathways converge. Previous studies have used coimmunoprecipitation to demonstrate interaction of the AhR and various STAT proteins
[109]. Thus, it is possible that IL-23 activates AhR/STAT interactions. Moreover,
determining the role of ROR-t in IL-22 immunity also warrants further investigation,
since controversy regarding the importance of ROR-t in IL-22 expression still exists [44,
45]. Duhen et al. reported low expression of RORC (ROR-γt in humans) in the IL-22
producing cells, and concluded that RORC is non-essential to IL-22 [44]. Conversely,
Trifari et al. used siRNA to demonstrate that silencing of RORC or AhR diminished IL22 production from memory CD4+ T cells [45].
To further decipher the intracellular mechanism of suppressed Th17 effector
cytokines following EtOH intoxication and burn injury, we determined whether
restitution of intracellular calcium and activation of PKC prevents the suppression of
Th17 effector function. Several lines of evidence suggest that the activation of PKC and
the sustained elevation of intracellular calcium are required for T cell activation [205,
206]. These studies suggest that signals emanating from TCR result in the activation of
protein tyrosine kinases and phospholipase C-γ [207, 208]. PLC-γ hydrolyzes
phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and 1,2diacylglycerol (DAG). IP3 causes a calcium release from intracellular stores followed by
calcium influx through the plasma membrane leading to a sustained elevation in
intracellular calcium concentration [207, 208]. DAG activates PKC [209]. In line with
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these findings, burn injury, regardless of EtOH, has been correlated with suppressed
intracellular calcium signaling [210]. Our current findings suggest that PP cells cultured
with plate bound anti-CD3 (5 µg/ml), soluble anti-CD28 (1 µg/ml) in the presence of
PMA (10 ng/ml) and ionomycin (50 ng/ml) restored IL-17 levels to that of sham vehicle
levels. On the other hand, PMA and ionomycin treatment did not affect IL-22. Together,
these data suggest the importance of effective intracellular Ca2+ influx and PKC
activation in the induction of IL-17. Furthermore, our findings support recent data
indicating differential regulation of IL-17 and IL-22. However the mechanism underlying
this divergent regulation of PP T cell IL-17 and IL-22 remains to be explored.
In summary, our findings suggest that ethanol combine with burn injury
differentially regulate the expression of PP T cell IL-17 and IL-22. While IL-22 is
successfully restored by restitution of IL-23, IL-17 restoration requires reestablishment of
PKC and intracellular calcium signaling. The divergent transcriptional regulation of IL17 and IL-22 may offer a target for immunomodulation in the treatment of patients who
sustain burn injury under the influence of EtOH intoxication. Specifically, IL-22’s role in
epithelial immune and barrier function maintenance, in addition to its transcription
regulation by AhR, offers a unique opportunity for targeted therapy. Among the ligands
for AhR are components of various vegetables, including broccoli, cabbage and brussel
sprouts [204]. Following injury, including EtOH and burn, these foods may be
incorporated into diet regimens to induce IL-22 and promote epithelial cell regeneration,
proliferation and boost innate immunity through induced expression of AMPs, without
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inducing pathogenic levels of IL-17. Thus, future studies will explore the translational
potential of modulating IL-22 following EtOH and burn injury.

CHAPTER FIVE
IL-22 MODULATES GUT EPITHELIAL AND IMMUNE BARRIER FUNCTIONS
FOLLOWING ACUTE ALCOHOL EXPOSURE AND BURN INJURY
Abstract
Interleukin (IL)–22 maintains gut epithelial integrity and expression of
antimicrobial peptides (AMPs) Reg3β and Reg3γ. Burn patients with a measureable
blood ethanol level at the time of hospital admission have an increased risk of morbidity.
Our lab has shown that acute alcohol/ethanol (EtOH) exposure prior to burn injury results
in increased gut permeability, intestinal T cell suppression and enhanced bacterial
translocation. Furthermore, we also found a decrease in intestinal IL-22 levels and Reg3β
and Reg3γ expression, which were not noted following ethanol or burn alone. We
examined whether in vivo restitution of IL-22 modulates gut permeability, Reg3β and
Reg3γ and bacterial load within the intestine following ethanol and burn injury. Male
mice, ~25g, were gavaged with EtOH (2.9 mg/kg) prior to receiving a ~12.5% TBSA full
thickness burn. Mice were immediately treated with saline control or IL-22 (1 mg/kg) by
i.p. injection. One day post injury animals were sacrificed and intestinal permeability,
Reg3β and Reg3γ expression and bacterial load measured. EtOH combined with burn
injury resulted in decreased expression of Reg3β and Reg3γ, as compared to sham injury.
This was attenuated following treatment with IL-22. Qualitatively, combined insult
resulted in increased bacterial load in intestine luminal content and intestine tissue, which
was prevented in half of IL-22 treated animals. IL-22 treatment also prevented increased
81
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gut permeability following ethanol and burn injury. Our data indicate that treatment with
IL-22 maintains gut epithelial and immune barrier integrity following ethanol and burn
injury; thus, the IL-22/AMP pathway may provide a novel therapeutic target for the
treatment of patients who sustain burn injury under the influence of EtOH.
Introduction
IL-22, a cytokine that uniquely does not act on immune cells, maintains gut
epithelial integrity and mucosal immunity by acting on epithelial cells. Specifically, IL22 is involved in chemotaxis [81], antimicrobial expression (AMP) [27-30], tissue repair
[73, 82] and epithelial cell survival [83, 84], proliferation [23] and differentiation [39].
Recent evidence further implicates IL-22 and IL-22-induced AMPs Reg3β and Reg3γ,
two C-type lectins, in the containment of Gram-negative and Gram-positive gut
pathogens [23, 29, 211, 212].
In the United States, more than one million burn injuries are reported yearly [1].
Nearly one-half of these injuries occur under the influence of alcohol/ethanol (EtOH)
intoxication [2-4, 6, 8, 11]. Burn victims who sustain injury post EtOH exposure exhibit
increased clinical complications, resulting in significantly longer hospital stays, more
surgical interventions and increased susceptibility to infection and higher morbidity [3, 4,
6, 11-13]. Moreover, patients with EtOH in their blood at the time of hospital admission
are more likely to die of smaller burns than non-EtOH exposed patients [2]. Though, the
mechanism(s) by which EtOH confounds clinical outcomes following burn injury
remain(s) unknown, previous data suggest that gut pathogens and their products may play
a pivotal role in the development of sepsis and multiple organ failure reported in burn and
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trauma patients [6, 14, 49-58]. In line with these studies, our laboratory has demonstrated
increased intestinal tissue damage, leakiness, and bacterial translocation as well as T
lymphocyte suppression following EtOH intoxication and burn injury [14-21]. Therefore,
further studies aimed at targeting the modulation of gut immune barrier function and
immunity are required to improve clinical outcomes of patients who sustain burn injury
under the influence of EtOH. Since IL-22 has been implicated in the maintenance of gut
epithelial barrier, perturbation of IL-22 or AMP expression following EtOH and burn
injury may severely impair the immune defense and barrier integrity.
Our present study evaluated the effects of EtOH and burn injury on gut IL-22
levels, leakiness, bacterial growth, and Reg3β and Reg3γ expression in our recently
established murine model [195]. Additionally, we have determined whether in vivo
treatment with rIL-22 prevents increased gut leakiness and bacterial growth and
modulates Reg3 expression following EtOH exposure and burn injury. Our results
provide a novel role for rIL-22 in the immunomodulation of gut barrier function, bacterial
containment and AMP expression. We found that when combined, EtOH and burn injury
resulted in decreased levels of IL-22 as well as decreased expression of Reg3β and Reg3γ
in the small intestine. We further confirmed that dual insult results in increased gut
leakiness and gut bacterial growth. IL-22 treatment successfully restored expression of
Reg3 and prevented increased gut permeability following combined EtOH exposure and
burn injury. Qualitatively, IL-22 treatment prevented increased gut bacterial load in half
of IL-22 treated animals. Thus, IL-22 maintains gut epithelial and immune barrier
integrity following EtOH and burn injury. The IL-22/AMP pathway may provide a novel

84
therapeutic target for the treatment of patients who sustain burn injury under the
influence of EtOH.
Material and Methods
Animals and reagents
Male C57BL/6 mice, 6-7 wks old, were obtained from Harlan Laboratories.
Recombinant IL-22 was obtained from GenScript (Piscataway, NJ). IL-22 ELISA kit was
obtained from R&D Systems (Minneapolis, MN). Protein Assay was obtained from BioRad (Hercules, CA). RNeasy Mini Kit was obtained from Qiagen (Valencia, CA).
TaqMan Expression Assays for Reg3γ, Regβ and GAPDH were obtained from Applied
Biosystems (Carlsbad, California). Fluorescein isothiocyanate (FITC)-conjugated dextran
was obtained from Sigma Aldrich (St. Louis, MO)
Treatment of mice with rIL-22 following EtOH and burn injury
As described in Chapter 4 [195], adult C57BL/6 male mice were randomly
divided to receive sham or burn injury and either ethanol (EtOH) or vehicle (water) to
yield four experimental groups: sham vehicle, sham EtOH, burn vehicle and burn EtOH.
Mice were gavaged with either 0.4 ml of 25% EtOH in water (~2.9 g/kg) or water. Four
hours after gavage, mice were anesthetized by i.p. injection of ketamine
hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg, respectively). Dorsal
surfaces were shaved, and animals were transferred into a template fabricated to expose
~12.5% of the TBSA. Immediately after sham or burn injury, a group of sham vehicle
and burn ethanol injured mice were treated with rIL-22 (1 mg/kg body weight in sterile
PBS, GenScript) by i.p. injection [47]. Animals were resuscitated with 1.0 ml
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physiological saline by i.p injection. Animals were allowed food and water ad libitum.
All experiments were conducted in accordance with the guidelines set forth in the Animal
Welfare Act and were approved by the Institutional Animal Care and Use Committee at
the Loyola University Health Sciences Division.
Measurement of intestinal tissue IL-22 levels
One day post injury, mice were anesthetized and the abdominal cavity exposed
via midline laparotomy and a 3-cm-long segment of small intestine was removed,
cleaned, snap-frozen in liquid nitrogen and stored at -70°C [20, 21]. Equal weights of
tissue (100 mg) from each experimental group were suspended in 1 mL of a buffer (PBS
containing protease inhibitor cocktail) and sonicated at 30 cycles twice for 30 sec on ice.
Homogenates were cleared by centrifuging at 12,000 rpm at 4°C. The supernatants were
stored at -70°C. Protein levels in the homogenates were determined using the Bio-Rad
Protein Assay. IL-22 levels in the intestinal tissue homogenates were measured by
enzyme-linked immunosorbent assay (ELISA) following manufacturer’s instructions.
Measurement of Reg3β and Reg3γ expression
One day post injury, mice were anesthetized and the abdominal cavity exposed
via midline laparotomy and a 1-cm-long segment of small intestine was removed,
cleaned, snap-frozen in liquid nitrogen and stored at -70°C [20, 21]. Equal weights of
tissue (25 mg) from each experimental group were used for RNA extraction using the
Qiagen RNeasy Mini Kit. RNA was quantified using a Nanodrop Spectrophotometer ND1000 and cDNA synthesized using the High Capacity Reverse Transcriptase Kit (Applied
Biosystems). Quantitative RT-PCR was performed with the Applied Biosystems 7500
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Fast Real-Time PCR system, using specific TaqMan Expression Assays (Applied
Biosystems) for Reg3β, Reg3γ and GAPDH. Values were then normalized to GAPDH
expression via the ΔΔCT method, as previously described [213].
In vivo gut permeability assay
A separate group of animals was used for the measurement of intestinal
permeability, with minor modifications to previously described method [20, 21]. One day
post sham or burn procedure and treatment with IL-22, animals were anesthetized and a
midline laparotomy performed. The renal artery and vein of both kidneys were ligated
and a 10 cm segment of small intestine (lower jejunum and ileum) isolated without
damaging intestinal and mesenteric structures. An 18 gauge intravenous catheter was
inserted into the isolated intestine. A solution of 4 kDa FITC-conjugated dextran in PBS
(100 µl of 25 mg/ml) was injected into the isolated small intestine. Blood samples were
collected from the heart 90 min post FITC-dextran injection and plasma FITC-dextran
concentration was determined using a fluorescence spectrophotometer at an excitation
wavelength of 480 nm and an emission wavelength of 520 nm. The plasma concentration
of FITC-dextran in each sample was calculated using a standard curve prepared from
dilutions of FITC-dextran in PBS.
Intestinal bacterial content
One day post injury, mice were anesthetized and the abdominal cavity exposed
via midline laparotomy and a 1-cm-long segment of small intestine, ileum, was
aseptically removed, cleaned and rinsed in sterile PBS one time. Tissues were weighed
and homogenized in sterile PBS (10 μl/mg tissue weight), one cycle for 30 sec.
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Separately, fecal luminal content was harvested from terminal small intestine, weighed
and resuspended in PBS (40 μl/mg fecal luminal content weight) by vortexing suspension
on high for 30 sec. 25 μl of intestinal tissue or fecal luminal content were plated and
cultured on trytic soy agar (TSA) or MacConkey agar for the analysis of total and Gram
negative bacteria, respectively, for 24 h at 37°C. Following incubation, TSA and
MacConkey agar plates were assessed for bacterial colony forming units (CFUs) and
photograped.
Statistical analysis
The data, wherever applicable, are presented as means + SEM and were analyzed
using ANOVA Tukey post-hoc test or Student’s test (GraphPad InStat). p<0.05 was
considered statistically significant.
Results
Intestinal tissue IL-22 is decreased following EtOH and burn injury
To determine whether EtOH and burn injury perturbs IL-22 in the intestinal tissue, we
measure IL-22 in intestinal tissue homogenates one day post EtOH exposure and burn
injury. As shown in Fig. 13, there was no difference in IL-22 in the intestinal tissue of
sham-injured animals, regardless of EtOH. However, while burn injury alone trended
towards an increase in intestinal IL-22, this was not found to be significantly different
from sham animals. The intestinal tissue from the EtOH burn group demonstrated
significantly decreased levels of IL-22, as compared to sham vehicle and burn vehicle
groups.
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Figure 13. Intestinal tissue IL-22 is decreased following EtOH and burn injury. One day
post insult, terminal small intestines were collected and equal weights of tissue (100 mg)
from each experimental group were suspended in 1 mL of a buffer (PBS containing
protease inhibitor cocktail) and sonicated. Homogenates were cleared by centrifugation
and supernatants were analyzed for IL-22 by ELISA (IL-22 ELISA Kits, R&D Systems).
IL-22 levels were normalized to protein levels. Values are means + SEM, n=6-9
animals/group from two independent experiments. *, p=0.0381 as compared with sham
vehicle by Student’s t test with Welch correction; †, p<0.01 as compared with burn
vehicle by ANOVA with Tukey’s post-hoc test.

Increased gut permeability one day post EtOH exposure and burn injury
Our laboratory has previously demonstrated increased gut permeability in a rat
model of EtOH exposure and burn injury [20, 21]. To confirm these findings in our
recently established mouse model [195], we measured intestinal permeability one day
after injury. The results presented in Fig. 14 indicate that there was no difference in the
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plasma FITC-dextran levels in either sham group. Similarly, plasma FITC-dextran levels
in burn vehicle group were also not found to be different from shams controls. However,
FITC-dextran levels were higher in burn ethanol group relative to other groups. These
results suggest that the combined insult of ethanol and burn increases intestinal
permeability when compared to either ethanol intoxication or burn injury alone.
Moreover, our findings confirm that similar to rats, mice also exhibit a disruption in the
intestinal barrier following ethanol and burn injury.

Figure 14. Increased gut permeability one day post EtOH exposure and burn injury. On
Day 1 after EtOH and burn injury, intestinal permeability was determined by monitoring
the transfer of FITC-dextran from the isolated intestinal lumen to the systemic
circulation, blood was drawn by cardiac puncture 90 min after FITC-dextran injection.
Values are means + SEM, n=4-5 animals/group. *, p<0.01 as compared to all groups by
ANOVA with Tukey’s post-hoc test.
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EtOH intoxication and burn injury suppresses intestinal AMP expression
Among the various AMPs regulated by IL-22, Reg3β and Reg3γ are key
components of gut mucosal immunity [29, 211, 214]. To determine whether EtOH
exposure and burn injury affects expression of Reg3β and Reg3γ we measured mRNA
levels of Reg3β and Reg3γ in small intestinal tissue one day following EtOH exposure
and burn injury. As demonstrated in Fig. 15, neither EtOH alone, nor burn injury alone
affect Reg3β and Reg3γ expression, as compared to sham injury. However, when
combined EtOH exposure and burn injury resulted in a significant suppression of Reg3β
and Reg3γ expression, as compared with sham vehicle. Thus, these data suggest that
EtOH and burn injury results in decreased intestinal AMP expression.
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Figure 15. Decreased intestinal AMP expression one day post EtOH and burn injury.
One day post injury, small intestine was harvested and equal weights of tissue (25 mg)
from each experimental group were used for RNA extraction using the Qiagen RNeasy
Mini Kit. Reg3β, Reg3γ and GAPDH were measured by qRT-PCR using specific probes.
AMP expression was normalized to GAPDH expression via the ΔΔCT method. Values
are means + SEM, n=3-10 animals/group from two independent experiments. *, p<0.05
as compared to sham vehicle; †, p<0.05 as compared to burn vehicle by ANOVA with
Tukey’s post-hoc test.
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Increased gut bacterial growth one day post EtOH exposure and burn injury
Previously, our laboratory has demonstrated increased gut bacterial translocation to
regional draining mesenteric lymph nodes following EtOH and burn injury [16, 18]. To
determine whether EtOH intoxication and burn injury facilitates gut bacterial growth, we
measured total and Gram-negative bacterial load in small intestinal tissue as well as in
small intestinal luminal content (feces). Intestinal tissue samples were weighed and
homogenized in PBS and luminal content samples weighed and resuspended in PBS.
Homogenates were cultured on specific agar plates for total (TSA) and Gram-negative
(MacConkey). We measured Gram-negative bacteria as they are the major cause of sepsis
and organ dysfunction in critically ill burn patients [215, 216]. As demonstrated in Fig.
16, our results show that EtOH and burn injury alone do not cause a significant change in
gut bacterial load. However, the combined insult of EtOH and burn injury resulted in a
robust increase in total (data not shown) and Gram-negative bacteria in the intestinal
tissue, as well as in the luminal content.
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Figure 16. Increased Gram-negative bacterial growth one day after EtOH exposure and
burn injury. One day post injury, a 1-cm-long segment of small intestine was aseptically
removed, cleaned and rinsed in sterile PBS. Tissues were weighed and homogenized in
sterile PBS (10 μl/mg tissue weight). Separately, fecal luminal content was harvested
from terminal small intestine, weighed and resuspended in PBS (40 μl/mg fecal luminal
content weight). 25 μl of intestinal tissue or fecal luminal content were plated and
cultured on MacConkey agar for the analysis of Gram-negative bacteria, for 24 h at 37°C.
Following incubation, plates were assessed for bacterial colony forming units (CFUs) and
photograped. Pictures are representative of n=5-9 animals/group.
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Treatment with IL-22
To perform these studies, sham vehicle and burn EtOH injured animals were
treated with IL-22 (1 mg/kg body weight) immediately after sham or burn injury. In these
and subsequent experiments, we did not include all four experimental groups. Rather, we
used only sham vehicle and burn EtOH, since only the burn EtOH group demonstrated
decreased intestinal IL-22, increased gut permeability and decreased AMP expression.
Treatment with IL-22 prevents increased gut permeability
The effect of IL-22 treatment on gut leakiness was observed one day post injury.
As demonstrated in Fig. 17, IL-22 treatment did not alter gut permeability in sham treated
animal. However, IL-22 treatment prevented the increase in plasma FITC-Dextran levels
following EtOH and burn injury. These data suggest that IL-22 prevents the increase in
gut permeability following EtOH exposure and burn injury.
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Figure 17. IL-22 treatment prevents increased gut permeability. In a group of sham
vehicle and burn EtOH animals, IL-22 (1 mg/kg body weight) was injected immediately
after injury. One day after EtOH and burn injury, intestinal permeability was determined
by monitoring the transfer of FITC-dextran from the isolated intestinal lumen to the
systemic circulation, blood was drawn by cardiac puncture 90 min after FITC-dextran
injection. Values are means + SEM, n=4-6 animals/group. *, p<0.05 as compared to all
groups by ANOVA with Tukey’s post-hoc test.

IL-22 treatment promotes intestinal AMP expression
To test whether IL-22 treatment modulates AMP expression one day following
EtOH and burn injury, small intestinal tissue was collected from saline control and IL-22
treated animals. Tissues were processed for RNA extraction and the expression of Reg3β
and Reg3γ analyzed by qRT-PCR. The results presented in Fig. 18 demonstrate that IL22 treatment does not affect expression of Reg3β or Reg3γ in sham animals. However,
IL-22 treatment prevented the suppression of Reg3β and Reg3γ expression in animals
that received EtOH and burn injury.
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Figure 18. Treatment with IL-22 prevents the decrease in intestinal AMP expression one
day post EtOH exposure and burn injury. Day one after injury and IL-22 treatment, small
intestine was harvested and equal weights of tissue (25 mg) from each experimental
group were used for RNA extraction using the Qiagen RNeasy Mini Kit. Reg3β, Reg3γ
and GAPDH were measured by qRT-PCR using specific probes. AMP expression was
normalized to GAPDH expression via the ΔΔCT method. Values are means + SEM, n=414 animals/group from three independent experiments. *, p<0.05 as compared to all
groups; †, p<0.05 as compared to sham vehicle; ‡, p<0.001 as compared to burn vehicle
by ANOVA with Tukey’s post-hoc test.
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Gut bacterial load and IL-22 treatment
Lastly, we examined whether IL-22 treatment has any relationship with gut bacterial
load. Small intestine tissue and luminal content were harvested from saline and IL-22
treated animals, one day post sham or EtOH and burn injury. Intestinal tissue samples
were weighed and homogenized in PBS and luminal content samples weighed and
resuspended in PBS. Homogenates were cultured on specific agar plates for total (TSA)
and Gram-negative (MacConkey) bacteria. As depicted in Fig. 19, IL-22 treatment did
not substantially affect Gram-negative bacterial growth in sham animals. However, 4 out
of 8 mice treated with IL-22 exhibited a substantial decrease in Gram-negative bacterial
load, both in the intestinal tissue samples and luminal content. IL-22 did not appreciably
affect total bacteria (data not shown). These findings suggest that the decrease in IL-22
may be responsible in part for the increase in gut bacterial load following EtOH and bun
injury.
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Figure 19. IL-22 treatment prevents increased Gram-negative bacterial growth in the
intestine. One day post injury and IL-22 treatment, a 1-cm-long segment of small
intestine was aseptically removed, cleaned weighed and homogenized in sterile PBS (10
μl/mg tissue weight). Separately, fecal luminal content was harvested from terminal small
intestine, weighed and resuspended in PBS (40 μl/mg fecal luminal content weight). 25 μl
of intestinal tissue or fecal luminal content were plated and cultured on MacConkey agar
for the analysis of Gram-negative bacteria, for 24 h at 37°C. Following incubation, plates
were assessed for bacterial colony forming units (CFUs) and photograped. Pictures are
representative of n=5-8 animals/group.
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Discussion
EtOH intoxication is a confounding factor in postburn pathogenesis. Yet, few
studies have evaluated the role of EtOH in post burn complications. In the present study,
we examined the role of EtOH intoxication on postburn gut permeability, intestine
expression of IL-22 and AMP expression as well as total and Gram-negative gut bacterial
load. Additionally, we treated animals with IL-22 to test whether it plays any role in the
modulation of gut barrier, immune function and bacterial containment following EtOH
and burn injury. We found that EtOH combined with burn injury resulted in a decrease in
intestinal tissue levels of IL-22 as well as suppression of Reg3β and Reg3γ expression, as
compared to sham injury. This was attenuated following treatment with IL-22. IL-22
treatment also prevented increased gut permeability following ethanol and burn injury.
The restoration of AMP and gut barrier was accompanied with a demonstrable decrease
in Gram-negative gut bacterial load in half of the animals treated with IL-22 after ethanol
and bun injury. Specifically, with IL-22 treatment samples continued to exhibit a
substantial increase in total bacteria (TSA) post EtOH and burn injury (data not shown);
yet, there was decreased growth of Gram-negative bacterial colonies in intestine tissue
homogenates and luminal content. This finding suggests Gram-negative bacteria are
likely controlled by IL-22 and/or AMPs. Thus, our data indicate that IL-22 treatment
maintains gut epithelial immune and barrier integrity following ethanol and burn injury.
Unlikely most cytokines, which exert their actions on immune cells, the IL-22
receptor is only expressed on epithelial cells of the skin, intestine, liver, pancreas, lung
and kidney [39, 73, 217]. IL-22 is of particular interest to gut immunity and barrier

100
integrity [39, 73]. The IL-22 receptor is composed of the IL-22R and IL-10R2 subunits
[73]. Binding of IL-22 to IL-22R1 induces its complex formation with IL-10R2 and
propagation of the JAK-STAT pathway, phosphorylation/homodimerization of STAT3
and subsequent activation of gene transcription [218]. Among the various genes activated
by IL-22 are AMPs, including Reg3β and Reg3γ, which are recognized for their role in
gut immunity and barrier integrity [23, 29, 211]. Moreover, IL-22 has been implicated in
tissue repair and regeneration. Therapeutically, IL-22 shows improvement in models of
EtOH induced liver injury, pancreatitis, hepatitis and inflammatory bowel disease [47,
83, 84, 149, 153, 154].
Our current data, suggests that IL-22 treatment modulates AMP expression,
bacterial load and gut permeability one day post EtOH exposure and burn. Together these
data highlight the critical role that IL-22 places in maintaining gut immune function and
barrier integrity. While further experiments will need to be performed to delineate a
mechanism by which IL-22 treatment improves intestinal AMP expression, bacterial load
and permeability, our data support the use of IL-22 as a therapeutic agent.
Mechanistically, it is likely that IL-22 maintains gut epithelial integrity through induction
of genes related to regeneration and proliferation in a STAT3 dependent manner.
Recently, our laboratory demonstrated IL-18 dependent increased apoptosis and altered
tight junction formation follow EtOH and burn injury [219]. It is likely that uncontrolled
IL-18 driven damage is due, in part, to decreased protective effects of IL-22. To
determine the mechanism by which IL-22 prevents increased gut permeability following
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EtOH and burn injury, future experiments will explore the role of IL-22 dependent
proliferation and regeneration in counterbalancing the damaging effects of IL-18.
In regards to immune function, it is possible that IL-22 exerts its action as a direct
immune modulator and through induction of AMP expression. Recently, IL-22 was
demonstrated to protect again K. pneumoniae infection, a Gram-negative gut pathogen
[23]. In vivo inoculation with K. pneumoniae induced IL-22 in the lungs of infected
animals, where blockage of IL-22 increased mortality as well as local and systemic
bacterial dissemination. In line with our current findings, Aujla et al. further
demonstrated a requirement for IL-23 in expression of IL-22 [23]. Following EtOH and
burn injury, it is possible that decreased intestinal IL-22, as presented in this study, may
facilitate survival of Gram-negative bacteria, including K. pneumoniae. Conversely, the
immuno-protective effects of IL-22 result from induction of Reg3β and Reg3γ. Initially,
Reg3β and Reg3γ were shown to bind peptidoglycan and kill Gram-positive bacteria
[211]. More recent evidence, suggest that IL-22 plays a role in protective against Gramnegative bacteria [29, 212], though the mechanism by which this occurs remains
unknown. Using an in vivo model of C. rodentium infection, a Gram-negative pathogen,
in IL-22 knockout mice, Zheng et al. demonstrated a requirement for IL-22 in survival of
C. rodentium [29]. IL-22 knockout mice demonstrated decreased survival, while
treatment with recombinant mouse Reg3γ-Ig fusion protein improved survival [29].
Previously, Reg3β was shown to induce aggregation of E. coli [212]. Together these data
suggest support the notion that Reg3β and Reg3γ play a role in the protection against
Gram-positive as well as Gram-negative bacteria. In our model, IL-22 dependent
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induction of Reg3β and Reg3γ correlated with decreased Gram-negative bacterial burden
in small intestinal tissue and luminal content. Further studies dissecting the role of Reg3β
and Reg3γ in the containment of gut Gram-negative bacteria are need. It is possible that
Reg3β and Reg3γ do not directly kill Gram-negative bacteria, but rather prevent their
invasion into intestinal crypts.
Our data indicate that IL-22 treatment prevents increased gut permeability and
increased bacterial load following EtOH exposure and burn injury. However, we
recognize that gut permeability did not return completely back to that of sham vehicle
animals following IL-22 treatment. Similarly, decreased bacterial load was only noted in
half of animals treated with IL-22. Together this suggests that suppression of IL-22 is
only one mechanism by which gut permeability is increased following EtOH and burn
injury. Other mechanisms that contribute to increased gut permeability and increased
bacterial load may include IL-18 mediated gut damage, such as neutrophil infiltration and
increased apoptosis, and suppression of other T helper cells, including Th1 interferon-γ
[15, 17, 20, 112, 219-221]. To test this possibility, future experiments will explore the
effects of combined anti-IL-18 antibody and IL-22 on gut barrier and immune function.
These studies will begin to identify a pathway by which to maintain proper gut
homeostasis combined EtOH exposure and burn injury.
In conclusion, our findings suggest that administration of IL-22 following EtOH
and burn injury prevents increased gut leakiness, gut bacterial load and decreased AMP
levels in the gut. While more studies are needed to elucidate the mechanism by which IL-
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22 influences these parameters, the IL-22/AMP pathway may provide a novel therapeutic
target for the treatment of patients who sustain burn injury under the influence of EtOH.

CHAPTER SIX
SUMMARY AND DISCUSSION
Ethanol and Burn Injury
More than one million burn injuries are reported yearly within the United States
[1]. These injuries result in approximately 500,000 emergency room visits and 40,000
hospitalizations annually [1]. Greater than 50% of these injuries occur under the
influence of alcohol/ethanol (EtOH) intoxication [2-11]. Burn victims who sustain injury
under the influence of EtOH exhibit significantly higher rates of morbidity and mortality
than patients without EtOH exposure at the time of injury [2-6, 11-13]. To date, the
mechanism by which EtOH confounds post burn clinical outcomes remains unclear.
Several lines of evidence suggest that gut pathogens and/or their products may play a
pivotal role in the subsequent development of sepsis and multiple organ failure reported
in burn and trauma patients [6, 14, 49-58]. In line with this hypothesis, our laboratory has
demonstrated increased intestinal tissue damage, leakiness and bacterial translocation as
well as intestinal T lymphocyte suppression following EtOH intoxication and burn injury
[14-21].
Th17 cells are implicated in gut homeostasis and in the containment of gut
pathogens. We investigated the effects of EtOH exposure and burn injury on intestine
associated lymphoid PP Th17 effector functions. We further examined whether in vivo
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modulation of IL-22 influences gut barrier function and bacterial load following EtOH
and burn injury.
Summary of Results
Our murine model of EtOH intoxication and burn injury demonstrates decreased
CD3/CD28 dependent expression of Th17 effector cytokines IL-17 and IL-22 in PP cells
one day post injury, Chapter 4. We further demonstrate restoration of IL-22 following
restitution of IL-23, as well as restoration of IL-17 in response to PMA and ionomycin.
Mechanistically, we found that IL-23 dependent induction of IL-22 is regulated, at least
in part, by the AhR, Fig. 20. While Th1 responses have been extensively studied in the
context of EtOH [141], trauma [111], burn [17, 18, 112, 116, 222, 223], and sepsis [144],
our current results are the first to demonstrate perturbation of Th17 responses following
EtOH exposure and burn injury. Our in vitro data further offer novel information
regarding the role of the AhR in regulation of IL-22.
While the exact mechanism by which EtOH and burn injury results in suppression
of IL-17 and IL-22 remain unclear, it is possible that EtOH modulates expression of IL23, a key molecule involved in Th17 differentiation. As presented in Chapter 3, we found
that EtOH exposure suppresses LPS-induced DC IL-23, in a dose dependent manner.
This observation agrees with previously published literature indicating suppression of IL23 in an in vivo model of EtOH exposure and pulmonary infection [135]. Additionally,
this data is recapitulated in our own in vivo model, where EtOH and burn injury resulted
in decreased IL-12/23p40 in supernatants harvested from PP mixed cells stimulated with
LPS. Though, IL-23p19 was measurable only at very low concentrations in cell lysates
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from LPS stimulated PP mixed cells obtained from sham animals, IL-23p19 was
undetectable in cell lysates from EtOH and burn injured mice. The direct measurement of
IL-23 has proved challenging to us and other investigators [135]. Nonetheless, these data
support our hypothesis that EtOH and burn injury perturbs IL-23 leading to suppression
of Th17 effector functions and contributing to decreased gut immune function and
increased gut damage, Fig. 20.
Recently, IL-22 has gained interest as a possible therapeutic agent. Specifically, IL22’s role in modulating epithelial cell proliferation, regeneration, immune function and
expression of AMPs [73], makes IL-22 a promising therapeutic target. Several
gastrointestinal disease models show improved outcomes following treatment with IL-22
[47, 83, 84, 149, 154]. In applying our observations to the modulation of Th17 effector
function in vivo, we further took advantage of our murine model to test whether in vivo
treatment with IL-22 improved gut barrier and immune functions following EtOH and
burn injury. As described in Chapter 5, we started by testing whether IL-22 dependent
expression of AMPs Reg3β and Reg3γ were affected by EtOH and burn injury. We found
decreased levels of Reg3β and Reg3γ, as well as increased gut permeability and bacterial
growth, one day post EtOH exposure and burn injury. In line with recent literature
highlighting the protective role of IL-22, we found increased expression of Reg3β and
Reg3γ, as well as decreased gut permeability and bacterial growth in animals treated with
IL-22. While these are correlative observations, they support the possible use of IL-22 as
therapeutic agent.
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Figure 20. Schematic of Th17/gut mucosal interactions. Under healthy conditions, IL-23
drives expression of Th17 cytokines, IL-17 and IL-22. These Th17 effector cytokines
maintain gut barrier integrity and immune function, as well as promote expression of
antimicrobial peptides, together these T cell effector functions prevent evasion of gut
microbes. Following ethanol and burn injury, we find an increase in gut bacterial and
increased gut permeability in the context of decreased IL-23, IL-17, IL-22 and
antimicrobial peptides Reg3β and Reg3γ.
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Suppressed Th17 Effector Function, Gut Bacterial
Translocation and Barrier Function
Several lines of evidence suggest that gut pathogens and their products play a
pivotal role in the development of sepsis and multiple organ failure reported in burn and
trauma patients [14, 59, 128, 193]. Therefore, the focus of our laboratory has been to
delineate the effects of EtOH exposure and burn injury on gut immune and barrier
function. To date, our laboratory has demonstrated increased intestinal tissue damage,
leakiness, and bacterial translocation to regional lymph nodes as well as T lymphocyte,
particularly T helper (Th) cell, suppression within 24 hours following EtOH intoxication
and burn injury [14-21, 112]. Specifically, ethanol combined with burn injury results in
decreased Th1 cytokine IFN-γ production [16, 17, 112].
Mechanistically, our laboratory has found a decrease in IL-12 to be the major
determinant in suppression of T cell effector functions, namely Th1 IFN-γ production
[17]. Increased IL-18, on the other hand, was found to cause neutrophil-dependent
intestinal barrier disruption as well as remote tissue damage, such as the lung, following
ethanol combined with burn injury [21, 46, 195, 219-221, 224]. Th17 cells are a third
subset of T helper cells and are implicated in cellular immunity, neutrophil recruitment
and clearance of bacteria as well as in epithelial cell integrity and tissue repair [36, 37,
48, 73]. Thus, in further dissecting T cell effector function and intestinal barrier integrity
following combined insult, our laboratory has recently focused on Th17 cells.
Our current findings indicating suppression of Th17 effector cytokines IL-17 and
IL-22 following combined EtOH exposure and burn injury complement our laboratory’s
earlier findings. In regards to increased bacterial translocation to MLN and gut leakiness,
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our current studies suggest that this may be due, at least in part, to perturbation of Th17
effector functions. Under healthy conditions, a few indigenous bacteria continuously
translocate to the MLN, but because of the intact immune defense these bacteria do not
survive. Decreased IL-17 and IL-22 following EtOH and burn injury, may allow for to
the passage of viable gut pathogenic bacteria across the epithelial barrier to MLN and
distant organs. Alternatively, IL-22 increases expression of AMPs, including Reg3β and
Reg3γ, which directly bind and kill bacteria [29, 30, 211]. In our data, we demonstrate
increased bacterial growth in the context of suppressed IL-22 and decreased expression of
Reg3β and Reg3γ. Following treatment with IL-22, we find decreased bacterial growth
and restoration of Reg3β and Reg3γ expression. It is possible that Reg3β and Reg3γ help
prevent evasion of gut microbes by limiting their invasion into intestinal crypts and
attachment to the gut epithelium.
In regards to intrinsic barrier function, it is possible that suppressed IL-17 and IL22 promotes gut leakiness. Decreased levels of IL-22 may facilitate epithelial barrier
dysfunction by altering the balance between epithelial cell renewal and loss. Under
normal conditions, the rapid rate of epithelial cell proliferation is counterbalanced by
apoptosis, thus maintaining the mucosal architecture and a constant number of cells.
Inappropriately high rates of intestinal epithelial cell apoptosis, such as those found after
EtOH and burn injury [219], or decreased proliferation may lead to an imbalance, thereby
causing intestinal tissue injury and facilitating gut leakiness and the evasion of gut
pathogens. Similarly, IL-17 has been implicated in the enhancement of tight junction
proteins [80]. Our laboratory has recently demonstrated that EtOH and burn injury alter
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intestinal tight junction protein phosphorylation in an IL-18 dependent manner [219].
Thus, it is plausible that IL-17 and IL-22 work to counteract the actions of IL-18 in vivo.
Following EtOH and burn injury, decreased IL-17 and IL-22 in the context of increased
IL-18 may promote epithelial cell apoptosis, decrease proliferation and deregulate tight
junction formation.
Future Directions
Our current data analyzing the effects of combined EtOH exposure and burn injury
on Th17 effector functions and their relationship with gut immune and barrier function
offer an opportunity for further exploration. Further studies can focus on determining
whether EtOH plus burn injury directly or indirectly affects DC expression of IL-23 or
whether our observation are intrinsic deficiencies in T cells and their ability to respond to
the local cytokine milieu. In regards to IL-23/AhR dependent modulation of IL-22, future
experiments should elucidate the molecular mechanism by which AhR regulates IL-23
dependent restoration of IL-22. In vivo potential studies include determining whether or
not IL-22 directly improves gut barrier function following EtOH and burn injury.
First it is necessary to delineate whether EtOH exposure and burn injury suppresses
IL-23. In the gut, DCs are likely the largest contributors of IL-23 [34]. Moreover, as
demonstrated in Chapter 3, EtOH suppresses BM-DC expression of IL-23 in a dose
dependent manner. Thus, it seems logical to test the effects of combined injury on PP DC
derived IL-23. However, given the small number of cell obtainable from PPs (~2 x 106
total cells/animal) and the low percent of CD11c+ DCs (~3% of total live events, Table1)
found in PP, it is not feasible to isolate a sufficient number of DCs from one animal.
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Therefore, to circumvent this challenge, future experiments would isolate CD11c DCs
+

from PPs and small intestine lamina propria. Isolating cells from PPs and lamina propria
would provide the opportunity to effectively isolate sufficient cells from all four
experimental groups to test whether combined injury suppresses DC ability to produce
IL-23 in response to antigenic challenge, such as LPS. If IL-23 were found to be affected
by combined injury, studies could be expanded to determine how EtOH and burn affect
DC derived IL-23. Utilizing current literature, these studies could explore the effects of
EtOH on TLR expression and downstream signaling, lipid raft formation, gene
expression, antigen presentation and/or expression of co-stimulatory receptor necessary
for efficient adaptive immune activation [158, 165-167, 188, 189, 225, 226].
In regards to IL-17 and IL-22, it is necessary to understand the relationship among
IL-23, STAT proteins, RORγt and the AhR. Though the AhR is essential for expression
of IL-22, it is still unclear how it modulates IL-22 and whether it plays a role in IL-17
expression [106, 107, 109]. Additionally, whether RORγt is necessary for IL-22
expression also remains controversial [44, 45]. Therefore, future experiments should
determine whether AhR utilizes ROR-γt and/or STAT3 in modulating IL-23-mediated
induction of IL-22. Though our current studies used PP mixed cells, future studies would
need to utilize purified PP T cells to accurately establish the regulation of IL-17 and IL22 in T cells. Our current data, demonstrating lack of IL-17 induction following IL-23
restitution, indicate that suppressed CD3 dependent expression of IL-17 and IL-22 may
be due to impaired intracellular signaling. Thus, initial experiments would explore the
effects of EtOH and burn injury on STAT3 phosphorylation, as well as RORγt and AhR
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expression. Later experiments will utilize an inhibitor to the AhR to determine whether
AhR regulates IL-23 dependent activation of STAT3 and/or expression of ROR-γt.
Finally, how AhR modulates IL-23 dependent induction of IL-22 will be determined by
testing whether AhR physically interacts with STAT3 and/or ROR-γt. Collectively, these
studies will elucidate the mechanism by which EtOH and burn injury impair Th17
immune responses, describe a pathway by which AhR modulates expression of IL-17
and/or IL-22, and determine whether or not ROR-γt is necessary for expression of IL-22.
Clinical Implications
The data presented herein, are applicable to variety of clinical settings and offer
novel information regarding IL-22 as a potential therapeutic. First, it is possible that Th17
effector functions are perturbed following injuries other than burn, such as trauma and
sepsis. In these situations, studying the in vivo effects of protective proteins, such as IL22, may provide new targets by which to decrease clinical complications related to
suppressed gut immune and barrier functions; thus, decreasing the development of sepsis
and multiple organ dysfunction and improving clinical outcomes and survival.
Conversely, if EtOH directly suppresses IL-17 and IL-22, investigating how this occurs
may prove applicable to the treatment of clinical diseases involving hyperactive Th17
dependent responses, such as inflammatory bowel disease, psoriasis, atopic dermatitis
and rheumatoid arthritis. In this arena, where immunomodulation remains at the forefront
of treatment, identifying a soluble molecule responsible for EtOH dependent immune
suppression may lead to the development of new therapeutic treatments. Our data,
demonstrating suppressed IL-17 and IL-22 following EtOH and burn injury and recusing
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of gut immune and barrier function with IL-22 treatment implicate IL-22 as a possible
therapeutic in the treatment of gastrointestinal related pathology.

APPENDIX A:
SUPPLEMENTAL DATA

[114]

[115]

Appendix 1A. Ethanol exposure did not influence the percentage of live cells. BM-DCs
(2 x 106 cell/well) were cultured in 96-well plates in the presence or absence of varying
concentrations of ethanol for 24 hours at 37°C. Cells were harvested and cell suspensions
were analyzed for cell viability by flow cytometry. Representative FACS plots were
taken from a single animal and demonstrate the percentage of viable cells within live gate
of total events collected. Numbers indicate the mean percentage of cells in live gate ±
SEM, n=4. p>0.05.

[116]

Appendix 2A. IL-17 secretion is decreased after EtOH intoxication and burn injury. PP
mixed cells (5x106 cells/mL) were cultured in the presence of T cell mitogen ConA
(5µg/mL) for 48hr at 37°C. Supernatants were harvested for measurements of IL-17.
Values are means ± SEM from two independent experiments, n=3-9 animals/group. *,
p<0.001 as compared with sham vehicle by ANOVA.

APPENDIX B:
SPECIFIC METHODS
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Mouse Model of Ethanol Intoxication and Thermal Injury
Adult C57BL/6 male mice (7-8 weeks old, 22-25 g body weight, Harlan Laboratories,
IN) were chosen randomly for all experiments. Animals received sham or burn injury and
either ethanol (EtOH) or vehicle (water) to yield four experimental groups: sham vehicle
(SV), sham EtOH (SE), burn vehicle (BV) and burn EtOH (BE). Mice were gavaged with
either 25% EtOH in water (~3 g/kg) or water. Four hours later, when blood EtOH levels
were in the range of 90-100 mg/dL, mice were anesthetized by intraperitoneal (i.p.)
injection of ketamine hydrochloride/Xylazine cocktail (~80 mg/kg and 1.2 mg/kg,
respectively), dorsum shaved, and transferred into a template fabricated to expose ~15%
of the total body surface area (TBSA). Burn-injured mice were immersed into a water
bath (85-87C) for ~7 seconds, which resulted in a 3rd degree full thickness scald injury.
Sham-injured mice were subjected to identical anesthesia and treatment, but immersed
into an isothermic water bath (37°C). Immediately after burn or sham procedure, mice
were resuscitated with i.p. injection of 1 mL physiologic saline. Animals were allowed
food and water ad libitum. Mice were sacrificed and organs collected one day post injury.

[119]
Growing Bone Marrow Dendritic Cells In Vitro
1. Sacrifice mice per protocol.
2. Sterilize the abdomen and hind legs with 70% ethanol.
3. Make an incision in the midline of the abdomen. Clip outward to expose the hind legs.
4. Dissect femurs from surrounding muscle tissue.
5. Place femurs (and/or tibia) from each mouse in a 1.5ml microcentrifuge tube
containing cold, sterile PBS.
From this point onwards, work in the tissue culture hood.
6. Cut off both ends of the each femur/tibia with a blade and flush the bone with 3 ml
media (without GM-CSF or IL-4) using a 22g needle and a 3mL syringe. (if use two
tibias and two femurs will have 12mL of media)
7. Pipette the bone marrow cells up and down to bring the cells into single-cell
suspension.
8. Pass the cells through a 70μm cell strainer. Wash the strainer with another 3 ml of
media (total 15mL of media)
9. Count cells using a hemocytometer (15mL). Wash cells once in complete media.
Adjust cell concentration to 2x106 cells/ml.
10. Plate 10x106 cells at a concentration of 2x106 cells/ml in a 100mm tissue culture petri
dish.
11. Differentiate cells in a humidified incubator with 5% CO2 at 37°C.
12. Feed cells at Day 2 with 5ml complete media. Wash cells and replace media every 23 days.
13. Harvest bone marrow DC’s between Day 7 and 10 using accutase and then cell
scraper.
14. Check for purity of DC by staining for the cell surface markers CD11c and MHC II
and analyze via flow cytometry.
Complete media: RMPI supplemented with 10% FBS, 1% Pen/Strep and L-glutamine
and 50ng/mL GM-CSF and 100U/mL IL-4 (~3ng/mL)
Notes: Expect about 60 million BM cells if use both femurs and both tibias.

[120]
Cell Preparation from PPs
Supplies
 HBSS Media
 Collagenase 1mg/ml
o Prepare enough to have 10mL per sample of PP (10mL per animal)
 Small petri dishes
 70μn nylon filter
 Syringe tops
 Conical tubes
 1.5mL microcentrifuge tubes
 Transfer pipets
 Tryptan blue
Procedures
1. Collect PP into conical tube containing 5mL plain HBSS
2. Add 5mL HBSS containing 1mg/ml Collagenase
3. H20 bath @ 37°C for 15 min
4. Crush PPs on nylon filter using syringe top
5. Collect cell suspension into new conical tube
6. Centrifuge suspension @ 4° 1200RPM for 15min
7. Discard supernatant
8. Re-suspend pellet in RPMI media (~10mL) - to wash
9. Centrifuge suspension @ 4° 1200RPM for 15min
10. Discard supernatant
11. Reconstitute cell pellet in 800µL RPMI media
12. Separate 10µL into microcentrifuge tube
13. Add 90µL tryptan blue to 10µL cell suspension
14. Count cells

[121]
Tissue Sonication Procedure
Media (PIC protease inhibitor cocktail in PBS – 1pill per 10mL of PBS)
1. Before you start do the following
a. Label one of the 2mL tubes for each sample
b. Label three 1.5mL eppendorf tubes for each sample
c. Make the PIC cocktail in PBS (do NOT use 10x PBS by mistake)
d. Turn on mini-centrifuge set to 4°C and press fast cool.
2. Take samples out of freezer and place box on a piece of dry ice so that the
samples do not thaw
3. Put each piece of tissue in 2mL tubes (make sure tissue weighs ~100mg)
4. Add 500µL PIC to each sample
5. Keep on ice
6. Sonicate for 30sec each, twice
a. KEEP dial between 3 and 4
b. Sonicate on ice (put ice into the small beaker and place 2mL tubes into
this beaker)
c. Make sure all the tissue is broken up – if not repeat cycle
d. Between samples dip sonicator in 70% alcohol and then in PBS
7. Add 500µL PIC to each sample – to total 1mL
8. Centrifuge 10,000 RPM for 15min @ 4°C
9. Transfer supernatant to new eppendorf tubes, aliquot 250µL per sample – collect
only the clear supernatant part – do not let the pipet touch the bottom (make 3
aliquot per sample)
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